polysaccharide sulfate - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	polysaccharide sulfate	go back to main search page
Accession:	CHEBI:37944	browse the term
Definition:	Any carbohydrate sulfate that is a polysaccharide carrying at least one O-sulfo substituent.
Synonyms:	related_synonym:	polysaccharide sulfates

show annotations for term's descendants Sort by:
Rat (1668) Mouse (1920) Human (1680) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (6) Green Monkey (0) Naked Mole-rat (0) All
Genes (1668)

carrageenan

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

increases phosphorylation
multiple interactions

Carrageenan results in increased phosphorylation of AKT1 protein
fucoxanthin inhibits the reaction [Carrageenan results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

multiple interactions
decreases expression

caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in decreased expression of ALB protein]; Indomethacin inhibits the reaction [Carrageenan results in decreased expression of ALB protein]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

annexin A1

affects response to substance
multiple interactions

ANXA1 protein affects the susceptibility to Carrageenan
ANXA1 protein affects the susceptibility to [Dexamethasone co-treated with Carrageenan]

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

amyloid P component, serum

increases expression

Carrageenan results in increased expression of APCS protein

NCBI chr13:85,373,219...85,374,195
Ensembl chr13:85,373,220...85,374,298

G

catalase

multiple interactions
decreases activity

fucoxanthin inhibits the reaction [Carrageenan results in decreased activity of CAT protein]
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in decreased activity of CAT protein]; Indomethacin inhibits the reaction [Carrageenan results in decreased activity of CAT protein]; procyanidin B2 inhibits the reaction [Carrageenan results in decreased activity of CAT protein]

PMID:26418808 PMID:28844677 PMID:34789018

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

multiple interactions
increases expression

5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of CCL2 protein]

PMID:12444156 PMID:20383154

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

multiple interactions
increases expression

5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of CCL3 protein]

PMID:12444156 PMID:20383154

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 5

increases expression
multiple interactions

Carrageenan results in increased expression of CCL5 protein
isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CCL5 protein]; Quercetin inhibits the reaction [Carrageenan results in increased expression of CCL5 protein]

PMID:12444156 PMID:14654164

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

chymase 1

multiple interactions
increases expression

adelmidrol inhibits the reaction [Carrageenan results in increased expression of CMA1 protein]

NCBI chr15:29,417,451...29,420,233
Ensembl chr15:29,417,451...29,420,233

G

C-reactive protein

increases expression
multiple interactions

Carrageenan results in increased expression of CRP protein
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of CRP protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of CRP protein]

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

C-X-C motif chemokine ligand 2

multiple interactions
increases secretion
increases expression

IMMLG5521 inhibits the reaction [Carrageenan results in increased secretion of CXCL2 protein]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of CXCL2 protein]

PMID:12444156 PMID:14654164 PMID:21549112

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

increases expression

Carrageenan results in increased expression of CXCL1 protein

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

early growth response 1

increases expression
multiple interactions

Carrageenan results in increased expression of EGR1 protein
3-(4-methylphenylsulfonyl)-2-propenenitrile inhibits the reaction [Carrageenan results in increased expression of EGR1 protein]; EGR1 protein inhibits the reaction [Carrageenan results in decreased expression of and affects the localization of TJP1 protein]; NFKBIA protein inhibits the reaction [Carrageenan results in increased expression of EGR1 protein]

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo(3,2-b)pyrid-5-one inhibits the reaction [Carrageenan results in increased expression of FOS protein]; Flurbiprofen inhibits the reaction [Carrageenan results in increased expression of FOS protein]; Flurbiprofen promotes the reaction [Urethane inhibits the reaction [Carrageenan results in increased expression of FOS protein]]; Urethane inhibits the reaction [Carrageenan results in increased expression of FOS protein]; Urethane inhibits the reaction [Flurbiprofen inhibits the reaction [Carrageenan results in increased expression of FOS protein]]

PMID:1327382 PMID:11164833

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

galanin and GMAP prepropeptide

decreases response to substance

GAL protein results in decreased susceptibility to Carrageenan

NCBI chr 1:200,650,439...200,655,302
Ensembl chr 1:200,650,439...200,654,959

G

G protein-coupled receptor 132

increases expression

Carrageenan results in increased expression of GPR132 mRNA

NCBI chr 6:131,924,061...131,943,327
Ensembl chr 6:131,924,160...131,942,168

G

G protein-coupled receptor 4

increases expression

Carrageenan results in increased expression of GPR4 mRNA

NCBI chr 1:78,865,376...78,877,126
Ensembl chr 1:78,865,409...78,876,599

G

G-protein coupled receptor 65

increases expression

Carrageenan results in increased expression of GPR65 mRNA

NCBI chr 6:117,515,786...117,536,514
Ensembl chr 6:117,515,648...117,536,512

G

heme oxygenase 1

multiple interactions
decreases expression

caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in decreased expression of HMOX1 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in decreased expression of HMOX1 mRNA]; procyanidin B2 inhibits the reaction [Carrageenan results in decreased expression of HMOX1 protein]
Carrageenan results in decreased expression of HMOX1 mRNA; Carrageenan results in decreased expression of HMOX1 protein

PMID:28844677 PMID:34789018

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein family A (Hsp70) member 1A

increases expression

Carrageenan results in increased expression of HSPA1A protein

NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227

G

intercellular adhesion molecule 1

multiple interactions
increases expression

2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Rosiglitazone inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of ICAM1 mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of ICAM1 mRNA]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of ICAM1 mRNA]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]; Rosiglitazone inhibits the reaction [Carrageenan results in increased expression of ICAM1 protein]
Carrageenan results in increased expression of ICAM1 mRNA; Carrageenan results in increased expression of ICAM1 protein

PMID:11181422 PMID:14709329 PMID:22330755 PMID:27803785 PMID:34789018

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 10

increases secretion
multiple interactions
increases expression

Carrageenan results in increased secretion of IL10 protein
indole-3-guanylhydrazone hydrochloride promotes the reaction [Carrageenan results in increased secretion of IL10 protein]; Indomethacin promotes the reaction [Carrageenan results in increased secretion of IL10 protein]
Indomethacin inhibits the reaction [Carrageenan results in increased expression of IL10 mRNA]; procyanidin B2 inhibits the reaction [Carrageenan results in increased secretion of IL10 protein]; Thioctic Acid promotes the reaction [Carrageenan results in increased expression of IL10 mRNA]

PMID:11181422 PMID:19735303 PMID:28844677 PMID:29499192

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 alpha

multiple interactions
decreases expression

Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]; Dexamethasone inhibits the reaction [Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]]; Dexamethasone inhibits the reaction [Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]]; Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]; Naloxone inhibits the reaction [Carrageenan inhibits the reaction [Morphine results in decreased expression of IL1A protein]]; Naloxone inhibits the reaction [Morphine inhibits the reaction [Carrageenan results in decreased expression of IL1A protein]]

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases secretion
increases expression
multiple interactions

Carrageenan results in increased secretion of IL1B protein
Carrageenan results in increased expression of IL1B mRNA; Carrageenan results in increased expression of IL1B protein
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; indole-3-guanylhydrazone hydrochloride inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]; Indomethacin inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; budlein A inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of IL1B mRNA]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; IMMLG5521 inhibits the reaction [Carrageenan results in increased secretion of IL1B protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of IL1B mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of IL1B protein]; N-(2-hydroxybenzoyl)tyramine inhibits the reaction [Carrageenan results in increased expression of IL1B protein]

PMID:11181422 PMID:16368644 PMID:17320857 PMID:20383154 PMID:21549112 More...

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions
increases expression
increases secretion

5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of IL6 protein]
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of IL6 protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Diclofenac inhibits the reaction [Carrageenan results in increased expression of IL6 protein]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of IL6 protein]; procyanidin B2 inhibits the reaction [Carrageenan results in increased secretion of IL6 protein]; Thiazolidines analog inhibits the reaction [Carrageenan results in increased expression of IL6 protein]

PMID:11181422 PMID:20383154 PMID:22330755 PMID:23774260 PMID:24412305 More...

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

kallikrein 1-related peptidase C10

multiple interactions
increases expression

procyanidin B2 inhibits the reaction [Carrageenan results in increased expression of KLK3 protein]

NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052

G

mitogen activated protein kinase 1

increases phosphorylation
multiple interactions

Carrageenan results in increased phosphorylation of MAPK1 protein
fucoxanthin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK1 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

multiple interactions
increases expression

caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of MAPK14 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of MAPK14 mRNA]

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

fucoxanthin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK3 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

matrix metallopeptidase 9

increases expression
multiple interactions

Carrageenan results in increased expression of MMP9 protein
adelmidrol inhibits the reaction [Carrageenan results in increased expression of MMP9 protein]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions
increases activity
increases expression

adelmidrol inhibits the reaction [Carrageenan results in increased activity of MPO protein]; arvelexin analog inhibits the reaction [Carrageenan results in increased expression of MPO protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of MPO mRNA]; Carrageenan inhibits the reaction [Raloxifene Hydrochloride results in increased activity of MPO protein]; Dexamethasone inhibits the reaction [Carrageenan results in increased activity of MPO protein]; Diclofenac inhibits the reaction [Carrageenan results in increased activity of MPO protein]; Ibuprofen inhibits the reaction [Carrageenan results in increased expression of MPO protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of MPO mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Carrageenan results in increased activity of MPO protein]; N-(2-hydroxybenzoyl)tyramine inhibits the reaction [Carrageenan results in increased activity of MPO protein]; Thiazolidines analog inhibits the reaction [Carrageenan results in increased activity of MPO protein]
Carrageenan results in increased expression of MPO mRNA; Carrageenan results in increased expression of MPO protein

PMID:9890637 PMID:15860553 PMID:18429935 PMID:23872256 PMID:24412305 More...

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

metallothionein 1

multiple interactions

[Methylnitrosourea co-treated with Carrageenan] results in increased expression of MT1 protein

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049

G

NFE2 like bZIP transcription factor 2

affects localization
decreases expression
multiple interactions

Carrageenan affects the localization of NFE2L2 protein
Carrageenan results in decreased expression of NFE2L2 mRNA
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in decreased expression of NFE2L2 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in decreased expression of NFE2L2 mRNA]; procyanidin B2 inhibits the reaction [Carrageenan affects the localization of NFE2L2 protein]

PMID:28844677 PMID:34789018

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

increases expression
multiple interactions

Carrageenan results in increased expression of NFKB1 mRNA
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of NFKB1 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of NFKB1 mRNA]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions

NFKBIA protein inhibits the reaction [Carrageenan results in increased expression of EGR1 protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nerve growth factor

increases expression
multiple interactions

Carrageenan results in increased expression of NGF protein
Dexamethasone inhibits the reaction [Carrageenan results in increased expression of NGF protein]

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nitric oxide synthase 2

multiple interactions
increases expression
increases activity

adelmidrol inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]; Carrageenan inhibits the reaction [Raloxifene Hydrochloride results in increased expression of NOS2 protein]; Carrageenan promotes the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of NOS2 mRNA]
fucoxanthin inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of NOS2 protein]
Carrageenan results in increased activity of NOS2 protein
Carrageenan results in increased expression of NOS2 mRNA; Carrageenan results in increased expression of NOS2 protein

PMID:7542281 PMID:9890637 PMID:15860553 PMID:18429935 PMID:22330755 More...

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NAD(P)H quinone dehydrogenase 1

decreases expression
multiple interactions

Carrageenan results in decreased expression of NQO1 protein
procyanidin B2 inhibits the reaction [Carrageenan results in decreased expression of NQO1 protein]

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

opioid receptor, mu 1

decreases expression

Carrageenan results in decreased expression of OPRM1 protein

NCBI chr 1:43,160,057...43,413,409
Ensembl chr 1:43,160,057...43,413,409

G

purinergic receptor P2X 7

multiple interactions

[(N-(1-(((cyanoimino)(5-quinolinylamino) methyl) amino)-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide) binds to and results in decreased activity of P2RX7 protein] which results in decreased susceptibility to Carrageenan

NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619

G

platelet and endothelial cell adhesion molecule 1

increases expression
multiple interactions

Carrageenan results in increased expression of PECAM1 protein
adelmidrol inhibits the reaction [Carrageenan results in increased expression of PECAM1 protein]

NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116

G

prostaglandin E synthase

multiple interactions
increases expression

arvelexin analog inhibits the reaction [Carrageenan results in increased expression of PTGES protein]

PMID:17258197 PMID:25451575

NCBI chr 3:14,177,892...14,189,236

G

prostaglandin E synthase 2

multiple interactions
increases activity

2-(4-chloro-6-(2,3-dimethylphenylamino)pyrimidin-2-ylthio)octanoic acid inhibits the reaction [[Carrageenan results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone]; [Carrageenan results in increased activity of PTGES2 protein] which results in increased chemical synthesis of Dinoprostone

NCBI chr 3:15,690,501...15,697,688
Ensembl chr 3:15,690,501...15,697,688

G

prostaglandin-endoperoxide synthase 2

multiple interactions
increases expression

3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Carrageenan inhibits the reaction [Raloxifene Hydrochloride results in increased expression of PTGS2 protein]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; dragon's blood inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Ketorolac inhibits the reaction [N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein]]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein]; nimesulide promotes the reaction [Carrageenan results in increased expression of PTGS2 protein]; Quercetin inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Resveratrol inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; Thioctic Acid inhibits the reaction [Carrageenan results in increased expression of PTGS2 mRNA]; triflusal inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]
fucoxanthin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of PTGS2 protein]
Carrageenan results in increased expression of PTGS2 mRNA; Carrageenan results in increased expression of PTGS2 protein

PMID:10101034 PMID:14654164 PMID:15860553 PMID:17258197 PMID:18814970 More...

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

increases phosphorylation
increases expression
increases localization
multiple interactions

Carrageenan results in increased phosphorylation of RELA protein
Carrageenan results in increased expression of RELA protein
Carrageenan results in increased localization of RELA protein
caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of RELA protein]; IMMLG5521 inhibits the reaction [Carrageenan results in increased localization of RELA protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of RELA protein]

PMID:21549112 PMID:22561171 PMID:34789018

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

selectin P

increases expression
multiple interactions

Carrageenan results in increased expression of SELP protein
imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of SELP protein]

NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845

G

somatostatin receptor 4

decreases response to substance

SSTR4 results in decreased susceptibility to Carrageenan

NCBI chr 3:135,854,826...135,856,689
Ensembl chr 3:135,854,826...135,856,689

G

signal transducer and activator of transcription 3

multiple interactions
increases expression

caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of STAT3 mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of STAT3 mRNA]

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

transforming growth factor, beta 1

increases secretion

Carrageenan results in increased secretion of TGFB1 protein

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tight junction protein 1

multiple interactions

3-(4-methylphenylsulfonyl)-2-propenenitrile promotes the reaction [Carrageenan results in decreased expression of and affects the localization of TJP1 protein]; Carrageenan results in decreased expression of and affects the localization of TJP1 protein; EGR1 protein inhibits the reaction [Carrageenan results in decreased expression of and affects the localization of TJP1 protein]

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

tumor necrosis factor

increases secretion
multiple interactions
increases expression

Carrageenan results in increased secretion of TNF protein
3-methylquercetin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; adelmidrol inhibits the reaction [Carrageenan results in increased expression of TNF protein]; budlein A inhibits the reaction [Carrageenan results in increased secretion of TNF protein]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of TNF mRNA]; caffeic acid phenethyl ester inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Dexamethasone inhibits the reaction [Carrageenan results in increased expression of TNF protein]; imisopasem manganese inhibits the reaction [Carrageenan results in increased expression of TNF protein]; IMMLG5521 inhibits the reaction [Carrageenan results in increased secretion of TNF protein]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of TNF mRNA]; Indomethacin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; isoquercitrin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; N-(2-hydroxybenzoyl)tyramine inhibits the reaction [Carrageenan results in increased expression of TNF protein]; procyanidin B2 inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Quercetin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Rutin inhibits the reaction [Carrageenan results in increased expression of TNF protein]; Thiazolidines analog inhibits the reaction [Carrageenan results in increased expression of TNF protein]
Carrageenan results in increased expression of TNF mRNA; Carrageenan results in increased expression of TNF protein
5S,12R,18R-trihydroxy-6Z,8E,10E,14Z,16E-eicosapentaenoic acid inhibits the reaction [Carrageenan results in increased expression of TNF protein]; diaoxinxuekang inhibits the reaction [Carrageenan results in increased expression of TNF protein]; indole-3-guanylhydrazone hydrochloride inhibits the reaction [Carrageenan results in increased secretion of TNF protein]; Indomethacin inhibits the reaction [Carrageenan results in increased secretion of TNF protein]

PMID:11181422 PMID:12444156 PMID:14654164 PMID:16368644 PMID:17320857 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular cell adhesion molecule 1

increases expression
multiple interactions

Carrageenan results in increased expression of VCAM1 mRNA
Dexamethasone inhibits the reaction [Carrageenan results in increased expression of VCAM1 mRNA]; Fluvoxamine inhibits the reaction [Carrageenan results in increased expression of VCAM1 mRNA]

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

dextran sulfate

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

4-aminobutyrate aminotransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABAT mRNA

NCBI chr10:6,996,688...7,092,835
Ensembl chr10:6,999,819...7,092,835

G

ATP binding cassette subfamily A member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA1 mRNA

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 11

decreases expression

Dextran Sulfate results in decreased expression of ABCB11 mRNA; Dextran Sulfate results in decreased expression of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

multiple interactions
decreases expression
increases response to substance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1A mRNA; ABCB1A protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
Dextran Sulfate results in decreased expression of ABCB1A mRNA
ABCB1A gene mutant form results in increased susceptibility to Dextran Sulfate

PMID:29950665 PMID:30102254 PMID:30701287 PMID:35093514

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1B mRNA; ABCB1B protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:29950665 PMID:30701287

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily B member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily B member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB6 mRNA

NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924

G

ATP binding cassette subfamily C member 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC10 mRNA

NCBI chr 9:14,657,242...14,677,178
Ensembl chr 9:14,657,264...14,677,178

G

ATP binding cassette subfamily C member 2

decreases expression
affects response to substance
multiple interactions

Dextran Sulfate results in decreased expression of ABCC2 mRNA; Dextran Sulfate results in decreased expression of ABCC2 protein
ABCC2 protein affects the susceptibility to Dextran Sulfate
ABCC2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:27580383 PMID:30701287

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

decreases expression
affects response to substance
multiple interactions

Dextran Sulfate results in decreased expression of ABCC3 mRNA; Dextran Sulfate results in decreased expression of ABCC3 protein
ABCC3 protein affects the susceptibility to Dextran Sulfate
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC3 mRNA; ABCC3 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]

PMID:27580383 PMID:29950665 PMID:30701287

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily C member 4

multiple interactions
decreases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ABCC4 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC4 mRNA
Dextran Sulfate results in decreased expression of ABCC4 mRNA; Dextran Sulfate results in decreased expression of ABCC4 protein

PMID:26271895 PMID:27580383 PMID:29950665

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

ATP binding cassette subfamily C member 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC5 mRNA

NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253

G

ATP binding cassette subfamily C member 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC6 mRNA

NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464

G

ATP binding cassette subfamily C member 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC9 mRNA

NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:175,532,547...175,655,356

G

ATP binding cassette subfamily F member 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ABCF2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABCF2 protein]

NCBI chr 4:10,594,802...10,607,620
Ensembl chr 4:10,594,907...10,607,606

G

ATP binding cassette subfamily G member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCG1 mRNA

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

ATP binding cassette subfamily G member 2

multiple interactions
decreases expression
affects response to substance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCG2 mRNA; ABCG2 protein affects the susceptibility to [Dextran Sulfate co-treated with 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine]
Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA]
Dextran Sulfate results in decreased expression of ABCG2 mRNA; Dextran Sulfate results in decreased expression of ABCG2 protein
ABCG2 protein affects the susceptibility to Dextran Sulfate

PMID:29950665 PMID:30701287 PMID:38423481

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

abl-interactor 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ABI1 protein]

NCBI chr17:85,098,837...85,179,829
Ensembl chr17:85,098,550...85,179,792

G

acetyl-CoA acyltransferase 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1A mRNA

NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624

G

acetyl-Coenzyme A acyltransferase 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1B mRNA

NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825

G

acetyl-CoA acyltransferase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA2 mRNA

NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249

G

acetyl-CoA carboxylase alpha

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ACACA protein]

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acyl-CoA dehydrogenase short chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADS mRNA

NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898

G

acyl-CoA dehydrogenase, short/branched chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADSB mRNA

NCBI chr 1:186,188,939...186,227,796
Ensembl chr 1:186,188,987...186,230,379

G

angiotensin I converting enzyme

multiple interactions
increases abundance

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACE mRNA
dextran sodium sulfate increases abundance of Ace protein in small and large intestine extracellular space

CTD
RGD

PMID:29950665 PMID:26401072

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

acetylcholinesterase

multiple interactions
decreases activity

[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of ACHE protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACHE mRNA
Dextran Sulfate results in decreased activity of ACHE protein

PMID:29950665 PMID:31226429 PMID:31807802

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

atypical chemokine receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR1 mRNA

NCBI chr13:85,782,396...85,784,015
Ensembl chr13:85,782,398...85,783,983

G

atypical chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR2 mRNA

NCBI chr 8:121,559,563...121,573,633
Ensembl chr 8:121,561,211...121,573,582

G

atypical chemokine receptor 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR3 mRNA

NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237

G

atypical chemokine receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACKR4 mRNA

NCBI chr 8:104,716,537...104,720,972
Ensembl chr 8:104,716,067...104,723,617

G

acyl-CoA synthetase bubblegum family member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSBG2 mRNA

NCBI chr 9:1,683,846...1,715,517
Ensembl chr 9:1,683,847...1,714,518

G

acyl-CoA synthetase medium-chain family member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACSM1 mRNA

NCBI chr 1:173,985,715...174,020,565
Ensembl chr 1:173,984,672...174,025,495

G

acyl-CoA synthetase medium-chain family member 3

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ACSM3 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACSM3 protein]

NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:174,133,288...174,160,184

G

acyl-CoA synthetase short-chain family member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS1 mRNA

NCBI chr 3:139,450,383...139,500,325
Ensembl chr 3:139,450,383...139,500,325

G

acyl-CoA synthetase short-chain family member 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS2 mRNA

NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675

G

actin-like 6A

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ACTL6A protein]

NCBI chr 2:115,492,374...115,508,401
Ensembl chr 2:115,492,285...115,508,401

G

actinin, alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN1 mRNA

NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251

G

actinin alpha 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN2 mRNA

NCBI chr17:58,143,334...58,210,622
Ensembl chr17:58,142,625...58,210,622

G

actin related protein 2

decreases expression

Dextran Sulfate results in decreased expression of ACTR2 protein

NCBI chr14:94,296,443...94,333,735
Ensembl chr14:94,296,443...94,340,524

G

actin related protein 3

decreases expression

Dextran Sulfate results in decreased expression of ACTR3 protein

NCBI chr13:36,800,739...36,843,837
Ensembl chr13:36,800,093...36,844,124

G

activin A receptor type 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACVR1 mRNA

NCBI chr 3:42,978,558...43,097,892
Ensembl chr 3:42,978,561...43,098,241

G

aminoacylase 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ACY1 protein

NCBI chr 8:107,072,354...107,077,756
Ensembl chr 8:107,072,358...107,077,682

G

adenosine deaminase

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ADA protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ADA protein]

NCBI chr 3:152,398,745...152,422,854
Ensembl chr 3:152,398,747...152,447,088

G

ADAM metallopeptidase domain 17

multiple interactions
increases expression
affects response to substance

ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of SIRT1 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in decreased expression of TIMP3 mRNA]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IFNG protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL17A protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL1B protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 protein]; ADAM17 protein affects the reaction [Dextran Sulfate results in increased expression of TNF protein]; resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of ADAM17 mRNA]
ADAM17 protein affects the susceptibility to Dextran Sulfate

NCBI chr 6:40,872,936...40,920,700
Ensembl chr 6:40,872,856...40,920,639

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS1 mRNA

NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103

G

ADAM metallopeptidase with thrombospondin type 1 motif, 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS14 mRNA

NCBI chr20:29,143,029...29,219,846
Ensembl chr20:29,144,354...29,219,866

G

ADAM metallopeptidase with thrombospondin type 1 motif, 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS2 mRNA

NCBI chr10:34,920,992...35,126,465
Ensembl chr10:34,921,049...35,123,821

G

ADAM metallopeptidase with thrombospondin type 1 motif, 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS4 mRNA

NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065

G

ADAM metallopeptidase with thrombospondin type 1 motif, 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS5 mRNA

NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205

G

adenylate cyclase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY2 mRNA

NCBI chr 1:34,375,639...34,822,252
Ensembl chr 1:34,375,895...34,822,236

G

adenylate cyclase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY4 mRNA

NCBI chr15:29,266,280...29,282,153
Ensembl chr15:29,266,287...29,282,108

G

adenylate cyclase 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCY6 mRNA

NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754

G

adenylate cyclase 7

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY7 mRNA
Dextran Sulfate results in decreased expression of ADCY7 mRNA

PMID:29950665 PMID:35093514

NCBI chr19:18,740,875...18,798,924
Ensembl chr19:18,740,875...18,776,311

G

adenylate cyclase activating polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCYAP1 mRNA

NCBI chr 9:113,102,632...113,122,500
Ensembl chr 9:113,103,718...113,109,773

G

ADCYAP receptor type I

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCYAP1R1 mRNA

NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:84,593,892...84,642,700

G

adhesion G protein-coupled receptor A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRA2 mRNA

NCBI chr16:64,932,964...64,971,433
Ensembl chr16:64,933,315...64,971,483

G

adhesion G protein-coupled receptor B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADGRB1 mRNA

NCBI chr 7:106,404,827...106,476,902
Ensembl chr 7:106,404,958...106,476,902

G

adhesion G protein-coupled receptor E1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of ADGRE1 protein
flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of ADGRE1 protein]

NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000

G

adhesion G protein-coupled receptor E5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRE5 mRNA

NCBI chr19:24,397,972...24,418,648
Ensembl chr19:24,398,689...24,418,638

G

adhesion G protein-coupled receptor F1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF1 mRNA

NCBI chr 9:17,661,258...17,696,359
Ensembl chr 9:17,660,930...17,711,704

G

adhesion G protein-coupled receptor F5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF5 mRNA

NCBI chr 9:17,517,596...17,624,107
Ensembl chr 9:17,520,009...17,623,968

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADH1 mRNA

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

alcohol dehydrogenase 5 (class III), chi polypeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADH5 mRNA

NCBI chr 2:226,975,184...226,987,591
Ensembl chr 2:226,947,466...226,987,591

G

adrenomedullin

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADM mRNA
Dextran Sulfate results in increased expression of ADM mRNA

PMID:29950665 PMID:35093514

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654

G

adenosine A2a receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA2A mRNA

NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386

G

adenosine A2B receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ADORA2B mRNA

NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772

G

adenosine A3 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA3 mRNA

NCBI chr 2:193,352,759...193,392,946
Ensembl chr 2:193,388,713...193,392,357

G

adrenoceptor alpha 2A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADRA2A mRNA

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

adrenoceptor beta 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ADRB2 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADRB2 mRNA

PMID:26271895 PMID:29950665

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

angiotensinogen

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AGT mRNA
Dextran Sulfate results in decreased expression of AGT mRNA

PMID:29950665 PMID:35093514

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

AHNAK nucleoprotein

decreases expression

Dextran Sulfate results in decreased expression of AHNAK mRNA

NCBI chr 1:205,882,225...205,970,934
Ensembl chr 1:205,882,273...205,970,926

G

aryl hydrocarbon receptor

multiple interactions
increases response to substance

AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL17A mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL1B mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of LCN2 mRNA]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of PTGS2 mRNA]
AHR gene mutant form results in increased susceptibility to Dextran Sulfate

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

alpha hemoglobin stabilizing protein

decreases expression

Dextran Sulfate results in decreased expression of AHSP protein

NCBI chr 1:182,879,901...182,885,508
Ensembl chr 1:182,880,076...182,885,506

G

adenylate kinase 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of AK1 protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of AK1 protein

NCBI chr 3:15,912,431...15,923,045
Ensembl chr 3:15,912,485...15,923,041

G

A-kinase anchoring protein 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP12 mRNA

NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:40,730,123...40,819,886

G

A-kinase anchoring protein 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP5 mRNA

NCBI chr 6:95,051,527...95,061,075
Ensembl chr 6:95,051,537...95,061,578

G

aldo-keto reductase family 1 member B1

decreases expression
increases expression
multiple interactions

Dextran Sulfate results in decreased expression of AKR1B1 protein
Dextran Sulfate results in increased expression of AKR1B1 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKR1B1 mRNA

PMID:29950665 PMID:35093514 PMID:35999755

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157

G

aldo-keto reductase family 1, member C3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C18 mRNA

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

AKT serine/threonine kinase 1

multiple interactions

[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein]
banxia xiexin decoction inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein; palmatine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased phosphorylation of AKT1 protein]

PMID:26262998 PMID:36806191

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

albumin

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ALB protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALB mRNA

PMID:29950665 PMID:35999755

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

aldehyde dehydrogenase 1 family, member A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1A1 mRNA

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

aldehyde dehydrogenase 1 family, member B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1B1 mRNA

NCBI chr 5:60,063,370...60,068,378
Ensembl chr 5:60,063,225...60,068,378

G

aldehyde dehydrogenase 2 family member

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH2 mRNA

NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521

G

aldehyde dehydrogenase 3 family, member A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH3A2 mRNA

NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281

G

aldehyde dehydrogenase 7 family, member A1

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ALDH7A1 protein]

NCBI chr18:50,003,242...50,042,193
Ensembl chr18:50,009,934...50,042,193

G

aldolase, fructose-bisphosphate C

decreases expression

Dextran Sulfate results in decreased expression of ALDOA protein; Dextran Sulfate results in decreased expression of ALDOC mRNA

PMID:35093514 PMID:35999755

NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066

G

arachidonate 12-lipoxygenase, 12S type

decreases expression

Dextran Sulfate results in decreased expression of ALOX12 protein

NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542

G

arachidonate 12-lipoxygenase, 12R type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX12B mRNA

NCBI chr10:53,863,060...53,874,938
Ensembl chr10:53,863,060...53,874,938

G

arachidonate 5-lipoxygenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5 mRNA

NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743

G

arachidonate 5-lipoxygenase activating protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5AP mRNA

NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986

G

alkaline phosphatase, biomineralization associated

multiple interactions
increases activity

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALPL mRNA
Dextran Sulfate results in increased activity of ALPL protein

PMID:29950665 PMID:30489199

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

angiopoietin 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANGPT4 mRNA

NCBI chr 3:140,420,389...140,454,213
Ensembl chr 3:140,420,389...140,453,583

G

angiopoietin-like 4

increases expression

Dextran Sulfate results in increased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

anoctamin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO1 mRNA

NCBI chr 1:199,751,439...199,900,099
Ensembl chr 1:199,751,439...199,900,069

G

anoctamin 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO10 mRNA

NCBI chr 8:121,841,664...121,960,739
Ensembl chr 8:121,841,665...121,962,670

G

anoctamin 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO6 mRNA

NCBI chr 7:126,933,919...127,113,588
Ensembl chr 7:126,933,936...127,113,589

G

anoctamin 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO7 mRNA

NCBI chr 9:93,917,524...93,945,323
Ensembl chr 9:93,917,524...93,945,323

G

anoctamin 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO9 mRNA

NCBI chr 1:196,208,863...196,230,381
Ensembl chr 1:196,197,341...196,229,900

G

annexin A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANXA1 mRNA

NCBI chr 1:217,861,175...217,877,205
Ensembl chr 1:217,861,175...217,877,343

G

annexin A4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANXA4 mRNA

NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:119,184,374...119,241,161

G

adaptor related protein complex 1 subunit mu 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AP1M1 mRNA

NCBI chr16:17,586,886...17,602,410
Ensembl chr16:17,584,730...17,602,403

G

adaptor related protein complex 1 subunit sigma 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of AP1S1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of AP1S1 protein]

NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713

G

APC regulator of WNT signaling pathway

affects response to substance
multiple interactions

APC affects the susceptibility to Dextran Sulfate; APC protein affects the susceptibility to Dextran Sulfate
[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form; [APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein; PDE4B protein affects the reaction [APC protein affects the susceptibility to Dextran Sulfate]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which affects the activity of MPO protein]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased chemical synthesis of PTEN protein modified form]; resorcinol inhibits the reaction [[APC protein affects the susceptibility to Dextran Sulfate] which results in increased phosphorylation of AKT1 protein]

PMID:16049979 PMID:26262998 PMID:30188895

NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696

G

amyloid P component, serum

increases expression

Dextran Sulfate results in increased expression of APCS protein

NCBI chr13:85,373,219...85,374,195
Ensembl chr13:85,373,220...85,374,298

G

apelin

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APLN mRNA
Dextran Sulfate results in decreased expression of APLN mRNA

PMID:29950665 PMID:35093514

NCBI chr X:127,180,801...127,213,567
Ensembl chr X:127,203,823...127,213,391

G

apolipoprotein A2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of APOA2 protein

NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355

G

apolipoprotein A4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of APOA4 protein
[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOA4 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of APOA4 protein]

PMID:32272095 PMID:35999755

NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469

G

apolipoprotein B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of APOB mRNA

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein C2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of APOC2 protein

NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476

G

apolipoprotein E

increases expression
multiple interactions

Dextran Sulfate results in increased expression of APOE protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of APOE protein]

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

amyloid beta precursor protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APP mRNA

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

aquaporin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP1 mRNA

NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690

G

aquaporin 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP11 mRNA

NCBI chr 1:152,046,515...152,056,675
Ensembl chr 1:152,046,517...152,056,725

G

aquaporin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP2 mRNA

NCBI chr 7:130,711,433...130,716,468
Ensembl chr 7:130,711,413...130,716,468

G

aquaporin 3 (Gill blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP3 mRNA

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

aquaporin 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP8 mRNA

NCBI chr 1:177,993,313...177,999,158
Ensembl chr 1:177,993,305...177,999,158

G

aquaporin 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP9 mRNA

NCBI chr 8:71,797,231...71,837,485
Ensembl chr 8:71,797,234...71,837,395

G

androgen receptor

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AR mRNA
Dextran Sulfate results in increased expression of AR mRNA

PMID:27920257 PMID:29950665

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

ARF GTPase 3

decreases expression

Dextran Sulfate results in decreased expression of ARF3 protein

NCBI chr 7:129,886,082...129,912,022
Ensembl chr 7:129,886,082...129,912,002

G

arginase 1

multiple interactions
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein]
Dextran Sulfate results in decreased expression of ARG1 mRNA; Dextran Sulfate results in decreased expression of ARG1 protein

PMID:25026504 PMID:38164749

NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422

G

Rho GTPase activating protein 1

decreases expression

Dextran Sulfate results in decreased expression of ARHGAP1 protein

NCBI chr 3:77,621,377...77,643,400
Ensembl chr 3:77,620,655...77,643,396

G

Rho GTPase activating protein 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP15 mRNA

NCBI chr 3:27,989,368...28,592,722
Ensembl chr 3:27,989,633...28,600,265

G

Rho GTPase activating protein 20

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP20 mRNA

NCBI chr 8:52,074,472...52,155,739
Ensembl chr 8:52,074,158...52,155,739

G

Rho GTPase activating protein 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP25 mRNA

NCBI chr 4:119,896,844...119,974,982
Ensembl chr 4:119,896,844...119,974,982

G

Rho GTPase activating protein 40

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP40 mRNA

NCBI chr 3:147,165,781...147,206,552
Ensembl chr 3:147,165,729...147,207,203

G

Rho GDP dissociation inhibitor alpha

decreases expression

Dextran Sulfate results in decreased expression of ARHGDIA protein

NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023

G

Rho GDP dissociation inhibitor beta

increases expression
decreases expression
multiple interactions

Dextran Sulfate results in increased expression of ARHGDIB mRNA
Dextran Sulfate results in decreased expression of ARHGDIB protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGDIB mRNA

PMID:23894361 PMID:29950665 PMID:35999755

NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:169,822,952...169,841,658

G

Rho guanine nucleotide exchange factor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF1 mRNA

NCBI chr 1:80,499,026...80,520,954
Ensembl chr 1:80,499,131...80,520,953

G

Rho guanine nucleotide exchange factor 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGEF12 mRNA

NCBI chr 8:43,350,070...43,475,404
Ensembl chr 8:43,353,799...43,476,366

G

Rac/Cdc42 guanine nucleotide exchange factor 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF6 mRNA

NCBI chr X:135,145,447...135,264,636
Ensembl chr X:135,146,786...135,275,304

G

ARF like GTPase 3

increases expression

Dextran Sulfate results in increased expression of ARL3 mRNA

NCBI chr 1:245,400,659...245,446,673
Ensembl chr 1:245,400,550...245,446,820

G

ARF like GTPase 9

increases expression

Dextran Sulfate results in increased expression of ARL9 mRNA

NCBI chr14:31,157,573...31,166,803
Ensembl chr14:31,157,586...31,166,699

G

actin related protein 2/3 complex, subunit 2

decreases expression

Dextran Sulfate results in decreased expression of ARPC2 protein

NCBI chr 9:75,820,782...75,851,471
Ensembl chr 9:75,820,770...75,851,471

G

actin related protein 2/3 complex, subunit 3

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of ARPC3 protein
Dextran Sulfate results in decreased expression of ARPC3 protein

NCBI chr12:34,172,780...34,186,651
Ensembl chr12:34,172,780...34,186,651

G

actin related protein 2/3 complex, subunit 4

decreases expression

Dextran Sulfate results in decreased expression of ARPC4 protein

NCBI chr 4:146,522,255...146,532,784
Ensembl chr 4:146,522,176...146,532,785

G

arrestin, beta 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of ARRB2 mRNA

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

arylsulfatase B

decreases expression

Dextran Sulfate results in decreased expression of ARSB mRNA

NCBI chr 2:25,002,210...25,162,675
Ensembl chr 2:25,002,346...25,162,671

G

ankyrin repeat and SOCS box-containing 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ASB2 mRNA

NCBI chr 6:122,474,754...122,511,014
Ensembl chr 6:122,474,756...122,510,854

G

acid sensing ion channel subunit family member 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ASIC4 mRNA

NCBI chr 9:76,941,532...76,962,900
Ensembl chr 9:76,941,532...76,962,900

G

argininosuccinate synthase 1

decreases expression

Dextran Sulfate results in decreased expression of ASS1 mRNA

NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903

G

autophagy related 5

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased secretion of IL1B protein]]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG5 mRNA]]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of ATG5 mRNA]

PMID:27611972 PMID:31676321 PMID:35439472

NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209

G

autophagy related 7

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]; 6-formylindolo(3,2-b)carbazole promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]; Leucine inhibits the reaction [alpinetin promotes the reaction [Dextran Sulfate results in increased expression of ATG7 mRNA]]

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase

decreases expression

Dextran Sulfate results in decreased expression of ATIC protein

NCBI chr 9:73,164,846...73,184,897
Ensembl chr 9:73,164,846...73,184,889

G

ATPase phospholipid transporting 10A (putative)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP10A mRNA

NCBI chr 1:109,556,760...109,730,440
Ensembl chr 1:109,556,782...109,730,437

G

ATPase phospholipid transporting 11B (putative)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP11B mRNA

NCBI chr 2:118,585,348...118,691,076
Ensembl chr 2:118,585,342...118,690,232

G

ATPase H+/K+ transporting non-gastric alpha2 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP12A mRNA

NCBI chr15:30,443,571...30,468,229
Ensembl chr15:30,443,571...30,468,229

G

ATPase Na+/K+ transporting subunit alpha 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A1 mRNA

NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837

G

ATPase Na+/K+ transporting subunit alpha 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A3 mRNA

NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918

G

ATPase Na+/K+ transporting subunit alpha 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1A4 mRNA

NCBI chr13:84,683,766...84,719,790
Ensembl chr13:84,683,768...84,719,687

G

ATPase Na+/K+ transporting subunit beta 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1B1 mRNA

NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459

G

ATPase Na+/K+ transporting subunit beta 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1B3 mRNA

NCBI chr 8:96,910,265...96,941,592
Ensembl chr 8:96,910,309...96,941,598

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP2A1 mRNA

NCBI chr 1:181,026,606...181,044,859
Ensembl chr 1:181,026,608...181,044,838

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2A3 mRNA

NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748

G

ATPase plasma membrane Ca2+ transporting 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2B1 mRNA

NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295

G

ATPase secretory pathway Ca2+ transporting 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ATP2C2 mRNA

NCBI chr19:47,754,120...47,811,369
Ensembl chr19:47,754,120...47,811,368

G

ATPase H+/K+ transporting subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP4B mRNA

NCBI chr16:76,144,150...76,153,063
Ensembl chr16:76,144,150...76,153,063

G

ATPase H+ transporting V0 subunit a2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V0A2 mRNA

NCBI chr12:31,947,220...31,979,875
Ensembl chr12:31,822,733...32,007,069

G

ATPase H+ transporting V0 subunit a4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0A4 mRNA

NCBI chr 4:66,760,163...66,842,126
Ensembl chr 4:66,760,159...66,842,110

G

ATPase H+ transporting V0 subunit D2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0D2 mRNA

NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354

G

ATPase H+ transporting V1 subunit E2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V1E2 mRNA

NCBI chr 6:7,667,359...7,673,711
Ensembl chr 6:7,667,564...7,672,626

G

ATPase H+ transporting V1 subunit F

increases expression

Dextran Sulfate results in increased expression of ATP6V1F mRNA

NCBI chr 4:58,067,666...58,070,628

G

ATPase H+ transporting V1 subunit G3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V1G3 mRNA

NCBI chr13:49,800,256...49,825,247
Ensembl chr13:49,794,222...49,825,247

G

ATPase copper transporting alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP7A mRNA

NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354

G

ATPase phospholipid transporting 8B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP8B1 mRNA

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

ATPase phospholipid transporting 8B2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP8B2 mRNA

NCBI chr 2:175,378,514...175,402,265
Ensembl chr 2:175,378,517...175,401,883

G

arginine vasopressin receptor 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1A mRNA

NCBI chr 7:58,114,306...58,118,230
Ensembl chr 7:58,114,284...58,122,215

G

arginine vasopressin receptor 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1B mRNA

NCBI chr13:43,046,531...43,059,046
Ensembl chr13:43,046,267...43,057,792

G

arginine vasopressin receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AVPR2 mRNA

NCBI chr X:151,633,501...151,636,155
Ensembl chr X:151,633,522...151,635,989

G

axin 2

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein]

NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of B3GNT3 mRNA

NCBI chr16:18,401,405...18,410,821
Ensembl chr16:18,401,405...18,410,766

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of B3GNT7 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of B3GNT7 protein]

NCBI chr 9:86,956,220...86,960,171
Ensembl chr 9:86,956,220...86,960,170

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of B3GNT8 mRNA

NCBI chr 1:81,135,602...81,138,501
Ensembl chr 1:81,135,499...81,142,263

G

bile acid CoA:amino acid N-acyltransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BAAT mRNA

NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685

G

barrier to autointegration nuclear assembly factor 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BANF1 protein]

NCBI chr 1:202,672,170...202,674,215
Ensembl chr 1:202,671,305...202,674,188

G

B-cell scaffold protein with ankyrin repeats 1

increases expression

Dextran Sulfate results in increased expression of BANK1 mRNA

NCBI chr 2:224,530,475...224,800,420
Ensembl chr 2:224,530,475...224,800,405

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX mRNA; [RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased expression of BAX protein; daphnetin inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased cleavage of BAX protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of BAX protein]

PMID:24146755 PMID:37209277 PMID:38583725

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

butyrylcholinesterase

multiple interactions
decreases activity

[Chlorpyrifos co-treated with Dextran Sulfate] results in decreased activity of BCHE protein
Dextran Sulfate results in decreased activity of BCHE protein

PMID:31226429 PMID:31807802

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; flavokawain B inhibits the reaction [Dextran Sulfate results in decreased expression of BCL2 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]

PMID:25449198 PMID:37209277 PMID:38583725

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BCL6, transcription repressor

multiple interactions

BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of JAK2 protein]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased phosphorylation of STAT3 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of and results in decreased secretion of IL10 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of ARG1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in decreased expression of MRC1 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL1B protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of IL6 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of and results in increased secretion of TNF protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of NOS2 protein]]

NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389

G

BAF chromatin remodeling complex subunit BCL7C

increases expression

Dextran Sulfate results in increased expression of BCL7C mRNA

NCBI chr 1:182,277,163...182,324,274
Ensembl chr 1:182,260,164...182,324,163

G

bradykinin receptor B1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB1 mRNA

NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747

G

bradykinin receptor B2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB2 mRNA

NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497

G

beclin 1

multiple interactions
increases expression

2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; [Dextran Sulfate co-treated with 6-formylindolo(3,2-b)carbazole] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein; [HU 308 co-treated with Dextran Sulfate] affects the expression of BECN1 protein; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; HU 308 promotes the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; Leucine inhibits the reaction [[Dextran Sulfate co-treated with alpinetin] results in increased expression of BECN1 protein]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]
dorsomorphin inhibits the reaction [Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]]; Nicotine promotes the reaction [Dextran Sulfate results in increased expression of BECN1 protein]

PMID:27611972 PMID:31676321 PMID:31926917

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

bestrophin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BEST1 mRNA

NCBI chr 1:206,629,340...206,646,085
Ensembl chr 1:206,629,500...206,646,063

G

biglycan

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BGN mRNA

NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461

G

bridging integrator 2

decreases expression

Dextran Sulfate results in decreased expression of BIN2 protein

NCBI chr 7:131,742,001...131,768,208
Ensembl chr 7:131,742,002...131,786,285

G

baculoviral IAP repeat-containing 5

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

baculoviral IAP repeat-containing 6

decreases expression

Dextran Sulfate results in decreased expression of BIRC6 mRNA

NCBI chr 6:20,722,922...20,916,396
Ensembl chr 6:20,722,922...20,916,434

G

bone morphogenetic protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP1 mRNA

NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776

G

bone morphogenetic protein 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP10 mRNA

NCBI chr 4:119,872,066...119,877,694
Ensembl chr 4:119,872,045...119,878,627

G

bone morphogenetic protein 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP7 mRNA

NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788

G

bone morphogenetic protein receptor type 1B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMPR1B mRNA

NCBI chr 2:230,538,252...230,871,077
Ensembl chr 2:230,541,558...230,871,368

G

bone morphogenetic protein receptor type 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BMPR2 mRNA

NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809

G

BPI fold containing family A, member 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of BPIFA1 protein

NCBI chr 3:142,627,810...142,633,553
Ensembl chr 3:142,627,810...142,633,552

G

B-box and SPRY domain containing

increases expression

Dextran Sulfate results in increased expression of BSPRY mRNA

NCBI chr 5:75,927,397...75,949,585
Ensembl chr 5:75,927,405...75,949,583

G

bone marrow stromal cell antigen 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BST1 mRNA

NCBI chr14:67,253,706...67,270,203
Ensembl chr14:67,252,998...67,270,180

G

basic transcription factor 3-like 4

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of BTF3L4 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of BTF3L4 protein]

NCBI chr 5:123,567,902...123,587,527
Ensembl chr 5:123,567,907...123,586,866

G

core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1 mRNA

NCBI chr 4:35,930,981...35,966,100
Ensembl chr 4:35,928,104...35,961,831

G

C1GALT1-specific chaperone 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1C1 mRNA

NCBI chr X:117,378,123...117,382,620
Ensembl chr X:117,375,525...117,382,787

G

complement C1q A chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QA mRNA

NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:149,133,636...149,136,534

G

complement C1q B chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QB mRNA

NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:149,118,846...149,124,407

G

C1q and TNF related 6

decreases expression

Dextran Sulfate results in decreased expression of C1QTNF6 mRNA

NCBI chr 7:110,077,867...110,084,584
Ensembl chr 7:110,077,878...110,084,412

G

complement C1s

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1S1 mRNA

NCBI chr 4:157,430,249...157,442,438
Ensembl chr 4:157,430,117...157,442,303

G

complement C3

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C3 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3 mRNA

PMID:29950665 PMID:35999755

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

complement C3a receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3AR1 mRNA

NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:156,075,389...156,084,701

G

complement C4B

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C4B mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of C4B protein]

PMID:29950665 PMID:32272095

NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681

G

complement component 4 binding protein, alpha

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of C4BPA protein

NCBI chr13:42,075,715...42,111,205
Ensembl chr13:42,075,717...42,111,205

G

complement C5a receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C5AR1 mRNA

NCBI chr 1:76,948,622...76,959,826

G

calcium binding protein 39

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAB39 mRNA

NCBI chr 9:86,463,095...86,524,545
Ensembl chr 9:86,463,095...86,524,544

G

calcium voltage-gated channel subunit alpha1 F

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CACNA1F mRNA

NCBI chr X:14,868,096...14,896,413
Ensembl chr X:14,868,024...14,896,413

G

calcium voltage-gated channel subunit alpha1 S

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CACNA1S mRNA

NCBI chr13:47,493,949...47,564,194
Ensembl chr13:47,493,949...47,564,318

G

calcitonin-related polypeptide alpha

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CALCA mRNA

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

calcitonin-related polypeptide, beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALCB mRNA

NCBI chr 1:168,965,383...168,970,259
Ensembl chr 1:168,966,465...168,970,125

G

calmodulin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALM1 mRNA

NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227

G

calmodulin 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CALM2 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CALM2 protein

NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287
Ensembl chr15:7,091,567...7,104,287

G

calreticulin

decreases expression

Dextran Sulfate results in decreased expression of CALR protein

NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414

G

calcium/calmodulin-dependent protein kinase II gamma

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK2G mRNA

NCBI chr15:3,504,017...3,563,050
Ensembl chr15:3,504,085...3,563,050

G

calcium/calmodulin-dependent protein kinase IV

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK4 mRNA

NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,585,269...24,802,487

G

calcium/calmodulin-dependent protein kinase kinase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMKK1 mRNA

NCBI chr10:57,637,335...57,660,498
Ensembl chr10:57,637,391...57,660,498

G

cyclase associated actin cytoskeleton regulatory protein 1

decreases expression

Dextran Sulfate results in decreased expression of CAP1 protein

NCBI chr 5:135,142,108...135,168,885
Ensembl chr 5:135,142,112...135,168,769

G

calpain 13

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CAPN13 protein]

NCBI chr 6:22,071,845...22,166,864
Ensembl chr 6:22,071,845...22,166,850

G

capping actin protein of muscle Z-line subunit beta

decreases expression

Dextran Sulfate results in decreased expression of CAPZB protein

NCBI chr 5:151,435,600...151,535,409
Ensembl chr 5:151,434,871...151,535,409

G

carbonic anhydrase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAR2 mRNA

NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818

G

carbonic anhydrase 3

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CA3 protein]

NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280

G

carbonic anhydrase 4

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CA4 protein]

NCBI chr10:69,827,945...69,836,501
Ensembl chr10:69,827,945...69,836,501

G

caspase 1

multiple interactions
increases expression

3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein]; [Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 mRNA; [Dextran Sulfate co-treated with Zearalenone] results in increased expression of CASP1 protein; [HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein; [Streptozocin co-treated with Dextran Sulfate] results in increased cleavage of CASP1 protein; ATG5 protein affects the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein; dorsomorphin inhibits the reaction [HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]]; HU 308 inhibits the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased activity of and results in increased cleavage of CASP1 protein]
Dextran Sulfate results in increased expression of CASP1 mRNA; Dextran Sulfate results in increased expression of CASP1 protein
celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide promotes the reaction [celastrol inhibits the reaction [Dextran Sulfate results in increased expression of CASP1 protein]]

PMID:27611972 PMID:30270565 PMID:32470352 PMID:34964214 PMID:37001609

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

increases cleavage
multiple interactions
increases activity

Dextran Sulfate results in increased cleavage of CASP3 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CASP3 mRNA; alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; biochanin A inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; daphnetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; gingerol inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; Leucine inhibits the reaction [alpinetin inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]]; Plant Extracts inhibits the reaction [Dextran Sulfate results in increased cleavage of CASP3 protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in increased activity of CASP3 protein]

PMID:21989142 PMID:27920257 PMID:28421826 PMID:29950665 PMID:31676321 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions
decreases expression

dihydrotanshinone I inhibits the reaction [Dextran Sulfate results in decreased expression of CASP8 protein]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

catalase

decreases activity
multiple interactions
increases activity

Dextran Sulfate results in decreased activity of CAT protein
[Streptozocin co-treated with Dextran Sulfate] results in decreased expression of CAT protein; Fatty Acids, Omega-3 inhibits the reaction [Dextran Sulfate results in increased activity of CAT protein]; gingerol inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; mangiferin inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Qingdai compound inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased activity of CAT protein]

PMID:27125760 PMID:28421826 PMID:30489199 PMID:31737179 PMID:34964214

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

caveolae associated protein 2

decreases expression

Dextran Sulfate results in decreased expression of CAVIN2 protein

NCBI chr 9:50,302,079...50,314,096
Ensembl chr 9:50,301,206...50,314,147

G

carbonyl reductase 1

decreases expression

Dextran Sulfate results in decreased expression of CBR1 protein

NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393

G

carbonyl reductase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CBR3 mRNA

NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875

G

coiled-coil domain containing 12

increases expression

Dextran Sulfate results in increased expression of CCDC12 mRNA

NCBI chr 8:110,635,276...110,686,417
Ensembl chr 8:110,635,710...110,686,417

G

coiled-coil domain containing 124

increases expression

Dextran Sulfate results in increased expression of CCDC124 mRNA

NCBI chr16:18,566,745...18,572,564
Ensembl chr16:18,566,745...18,572,564

G

coiled-coil domain containing 13

increases expression

Dextran Sulfate results in increased expression of CCDC13 mRNA

NCBI chr 8:121,455,202...121,507,487
Ensembl chr 8:121,457,697...121,502,337

G

coiled-coil domain containing 158

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CCDC158 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CCDC158 protein]

NCBI chr14:15,411,178...15,468,579
Ensembl chr14:15,411,163...15,468,581

G

coiled-coil domain containing 88B

increases expression

Dextran Sulfate results in increased expression of CCDC88B mRNA

NCBI chr 1:204,036,913...204,052,878
Ensembl chr 1:204,036,918...204,052,970

G

coiled-coil domain containing 9

increases expression

Dextran Sulfate results in increased expression of CCDC9 mRNA

NCBI chr 1:76,978,312...76,991,673
Ensembl chr 1:76,974,091...76,991,607

G

coiled-coil domain containing 96

increases expression

Dextran Sulfate results in increased expression of CCDC96 mRNA

NCBI chr14:74,276,568...74,279,072
Ensembl chr14:74,276,960...74,278,888

G

coiled-coil alpha-helical rod protein 1

increases expression

Dextran Sulfate results in increased expression of CCHCR1 mRNA

NCBI chr20:3,205,675...3,218,437
Ensembl chr20:3,205,676...3,218,308

G

cholecystokinin B receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCKBR mRNA

NCBI chr 1:159,771,733...159,781,738
Ensembl chr 1:159,771,733...159,814,881

G

C-C motif chemokine ligand 11

increases secretion
increases expression
multiple interactions

Dextran Sulfate results in increased secretion of CCL11 protein
Dextran Sulfate results in increased expression of CCL11 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL11 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL11 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL11 protein]

PMID:21858153 PMID:29950665 PMID:32033881

NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926

G

C-C motif chemokine ligand 2

multiple interactions
increases expression
increases secretion

[RASSF1 gene mutant form results in increased susceptibility to Dextran Sulfate] which results in increased secretion of CCL2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL2 mRNA; flavokawain B inhibits the reaction [Dextran Sulfate results in increased expression of CCL2 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CCL2 protein]

PMID:19645018 PMID:20079348 PMID:21858153 PMID:24146755 PMID:29950665 More...

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 21

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL21A mRNA

NCBI chr 5:56,980,557...56,981,661
Ensembl chr 5:56,980,558...56,981,686

G

C-C motif chemokine ligand 24

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL24 mRNA

NCBI chr12:21,100,835...21,104,832
Ensembl chr12:21,100,835...21,104,893

G

C-C motif chemokine ligand 25

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL25 mRNA

NCBI chr12:2,707,398...2,716,571
Ensembl chr12:2,707,398...2,716,554

G

C-C motif chemokine ligand 27

increases expression

Dextran Sulfate results in increased expression of CCL27A mRNA

NCBI chr 5:56,941,402...56,948,511
Ensembl chr 5:56,941,402...56,948,506

G

C-C motif chemokine ligand 28

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL28 mRNA

NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997

G

C-C motif chemokine ligand 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CCL3 mRNA
ligustilide inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]; Mesalamine inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 mRNA]
Dextran Sulfate results in increased expression of CCL3 protein
Hesperidin inhibits the reaction [Dextran Sulfate results in increased expression of CCL3 protein]

PMID:19645018 PMID:30811821 PMID:33130971

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL4 mRNA

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

C-C motif chemokine ligand 7

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CCL7 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL7 mRNA; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CCL7 mRNA]

PMID:19645018 PMID:29950665 PMID:32033881

NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303

G

C-C motif chemokine ligand 9

increases expression
decreases expression

Dextran Sulfate results in increased expression of CCL6 mRNA
Dextran Sulfate results in decreased expression of CCL6 mRNA

PMID:19645018 PMID:35093514

NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369

G

cyclin D1

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein; [Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein]; obeticholic acid inhibits the reaction [[Dietary Fats co-treated with Dextran Sulfate] results in decreased expression of CCND1 protein]

PMID:31715269 PMID:35439472

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

C-C motif chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR2 mRNA

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

C-C motif chemokine receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR4 mRNA

NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:114,176,974...114,178,056

G

C-C motif chemokine receptor 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR5 mRNA

NCBI chr 8:123,752,423...123,757,538
Ensembl chr 8:123,752,325...123,759,260

G

C-C motif chemokine receptor 7

multiple interactions

Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 mRNA]; Melatonin inhibits the reaction [Dextran Sulfate results in increased expression of CCR7 protein]

NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309

G

C-C motif chemokine receptor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR8 mRNA

NCBI chr 8:119,826,332...119,828,292
Ensembl chr 8:119,826,568...119,827,629

G

C-C motif chemokine receptor like 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCRL2 mRNA

NCBI chr 8:111,034,279...111,036,914
Ensembl chr 8:111,034,279...111,036,664

G

centriole, cilia and spindle-associated protein

increases expression

Dextran Sulfate results in increased expression of CCSAP mRNA

NCBI chr19:51,824,954...51,843,469
Ensembl chr19:51,826,994...51,842,753

G

CD14 molecule

affects response to substance
multiple interactions

Dextran Sulfate affects the susceptibility to CD14 protein
[Dextran Sulfate affects the susceptibility to CD14 protein] which affects the expression of IFNG mRNA; CD14 protein inhibits the reaction [Dextran Sulfate results in increased expression of TNF mRNA]

NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261

G

CD163 molecule

increases expression

Dextran Sulfate results in increased expression of CD163 mRNA

NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878

G

CD177 molecule

increases expression

Dextran Sulfate results in increased expression of CD177 mRNA

NCBI chr 1:80,340,034...80,360,599
Ensembl chr 1:80,340,034...80,360,621

G

CD180 molecule

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CD180 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD180 mRNA

PMID:23894361 PMID:29950665

NCBI chr 2:33,855,940...33,870,046
Ensembl chr 2:33,855,991...33,899,936

G

CD19 molecule

increases expression

Dextran Sulfate results in increased expression of CD19 mRNA

NCBI chr 1:180,987,286...180,993,920
Ensembl chr 1:180,987,286...180,993,975

G

Cd200 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD200 mRNA

NCBI chr11:55,410,166...55,437,527
Ensembl chr11:55,410,196...55,501,648

G

Cd247 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD247 mRNA

NCBI chr13:78,043,302...78,118,437
Ensembl chr13:78,043,307...78,122,263

G

CD274 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD274 mRNA

NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:227,116,649...227,134,450

G

Cd28 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD28 mRNA

NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685

G

CD34 molecule

decreases expression

Dextran Sulfate results in decreased expression of CD34 mRNA

NCBI chr13:106,480,313...106,500,844
Ensembl chr13:106,480,043...106,499,832

G

Cd4 molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD4 mRNA

NCBI chr 4:157,668,878...157,695,366

G

CD44 molecule

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of CD44 mRNA

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

CD52 molecule

increases expression

Dextran Sulfate results in increased expression of CD52 mRNA

NCBI chr 5:146,319,789...146,321,348
Ensembl chr 5:146,319,969...146,321,348

G

Cd53 molecule

increases expression

Dextran Sulfate results in increased expression of CD53 mRNA

NCBI chr 2:194,352,139...194,399,668
Ensembl chr 2:194,352,139...194,399,657

G

CD55 molecule (Cromer blood group)

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD55 mRNA

NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831

G

Cd68 molecule

increases expression

dextran sulfate increases expression of CD68 protein in colonic lamina propria of mice

RGD

NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697

G

Cd72 molecule

increases expression

Dextran Sulfate results in increased expression of CD72 mRNA

NCBI chr 5:57,697,361...57,704,980
Ensembl chr 5:57,697,367...57,704,725

G

CD74 molecule

increases expression
decreases expression

Dextran Sulfate results in increased expression of CD74 mRNA
Dextran Sulfate results in decreased expression of CD74 mRNA

PMID:23894361 PMID:35093514

NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003

G

CD79a molecule

increases expression

Dextran Sulfate results in increased expression of CD79A mRNA

NCBI chr 1:80,493,581...80,497,936
Ensembl chr 1:80,493,581...80,497,935

G

CD79b molecule

increases expression

Dextran Sulfate results in increased expression of CD79B mRNA

NCBI chr10:91,239,354...91,242,500
Ensembl chr10:91,239,356...91,242,625

G

Cd81 molecule

decreases expression

Dextran Sulfate results in decreased expression of CD81 mRNA

NCBI chr 1:198,235,861...198,251,660
Ensembl chr 1:198,241,484...198,251,660

G

CD86 molecule

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD86 mRNA; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]]; IRF4 protein inhibits the reaction [BCL6 protein inhibits the reaction [Dextran Sulfate results in increased expression of CD86 protein]]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 mRNA]; IRF4 protein promotes the reaction [Dextran Sulfate results in increased expression of CD86 protein]
Dextran Sulfate results in increased expression of CD86 mRNA; Dextran Sulfate results in increased expression of CD86 protein

PMID:29950665 PMID:38164749

NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818

G

cytidine deaminase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDA mRNA

NCBI chr 5:150,556,615...150,583,231
Ensembl chr 5:150,556,615...150,583,231

G

cadherin 1

multiple interactions
decreases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in decreased expression of CDH1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH1 mRNA
Dextran Sulfate results in decreased expression of CDH1 mRNA; Dextran Sulfate results in decreased expression of CDH1 protein

PMID:29950665 PMID:34273909 PMID:36543318 PMID:37385329

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 2

multiple interactions
increases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CDH2 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH2 protein

PMID:34273909 PMID:36543318

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

G

cadherin 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH5 mRNA

NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368

G

cadherin-related family member 2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CDHR2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CDHR2 protein]

NCBI chr17:9,876,853...9,913,356
Ensembl chr17:9,876,860...9,912,575

G

cyclin-dependent kinase 11B

increases expression

Dextran Sulfate results in increased expression of CDK11B mRNA

NCBI chr 5:166,212,761...166,238,883
Ensembl chr 5:166,212,829...166,238,876

G

cyclin-dependent kinase inhibitor 1C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDKN1C mRNA

NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048

G

caudal type homeo box 2

increases expression
decreases expression
multiple interactions

Dextran Sulfate results in increased expression of CDX2 protein
Dextran Sulfate results in decreased expression of CDX2 protein
6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CDX2 protein]; nitazoxanide inhibits the reaction [Dextran Sulfate results in decreased expression of CDX2 protein]

PMID:29680209 PMID:38663798

NCBI chr12:7,726,798...7,733,142
Ensembl chr12:7,726,798...7,733,142

G

CCAAT/enhancer binding protein delta

increases expression

Dextran Sulfate results in increased expression of CEBPD mRNA

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

carboxyl ester lipase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CEL mRNA

NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:11,883,532...11,891,035

G

centrosomal protein 131

increases expression

Dextran Sulfate results in increased expression of CEP131 mRNA

NCBI chr10:105,346,015...105,370,380
Ensembl chr10:105,346,015...105,370,380

G

carboxylesterase 1D

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CES1D protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES1D mRNA
Dextran Sulfate results in decreased expression of CES1D mRNA

PMID:29950665 PMID:35093514 PMID:35999755

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

carboxylesterase 2C

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2C mRNA

NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:260,388,902...260,398,790

G

carboxylesterase 2E

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2E mRNA

NCBI chr19:157,447...172,822
Ensembl chr19:157,407...172,856

G

cilia and flagella associated protein 45

increases expression

Dextran Sulfate results in increased expression of CFAP45 mRNA

NCBI chr13:84,989,474...85,012,880
Ensembl chr13:84,981,728...85,012,878

G

complement factor B

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFB protein

NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505

G

complement factor D

increases expression

Dextran Sulfate results in increased expression of CFD protein

NCBI chr 7:9,813,148...9,814,871
Ensembl chr 7:9,813,150...9,815,053

G

complement factor H

multiple interactions
increases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CFH protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CFH mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CFH protein]
Dextran Sulfate results in increased expression of CFH mRNA; Dextran Sulfate results in increased expression of CFH protein

PMID:29950665 PMID:32272095 PMID:35093514 PMID:35999755

NCBI chr13:51,512,376...51,613,829
Ensembl chr13:51,511,828...51,613,838

G

cofilin 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CFL1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CFL1 protein

NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587

G

CASP8 and FADD-like apoptosis regulator

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

CF transmembrane conductance regulator

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFTR mRNA

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

cell growth regulator with EF hand domain 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of CGREF1 protein

NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852

G

chromatin assembly factor 1 subunit A

increases expression

Dextran Sulfate results in increased expression of CHAF1A mRNA

NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654

G

calcium homeostasis endoplasmic reticulum protein

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHERP protein]

NCBI chr16:17,367,455...17,380,507
Ensembl chr16:17,367,455...17,380,507

G

charged multivesicular body protein 2A

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CHMP2A protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CHMP2A protein]

NCBI chr 1:73,660,045...73,662,894
Ensembl chr 1:73,660,046...73,662,452

G

charged multivesicular body protein 4B

increases expression

Dextran Sulfate results in increased expression of CHMP4B mRNA

NCBI chr 3:143,170,859...143,211,376
Ensembl chr 3:143,170,902...143,210,844

G

chimerin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHN2 mRNA

NCBI chr 4:83,148,616...83,407,711
Ensembl chr 4:83,147,983...83,407,709

G

chordin-like 2

increases expression

Dextran Sulfate results in increased expression of CHRDL2 mRNA

NCBI chr 1:154,343,201...154,370,651
Ensembl chr 1:154,343,201...154,370,640

G

cholinergic receptor, muscarinic 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRM4 mRNA

NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:77,893,425...77,901,159

G

cholinergic receptor nicotinic alpha 2 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA2 mRNA

NCBI chr15:40,342,317...40,358,601
Ensembl chr15:40,342,317...40,358,601

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA7 mRNA

NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240

G

cholinergic receptor nicotinic beta 3 subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRNB3 mRNA

NCBI chr16:64,713,438...64,751,360
Ensembl chr16:64,714,169...64,751,360

G

cholinergic receptor nicotinic epsilon subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNE mRNA

NCBI chr10:55,331,211...55,339,923
Ensembl chr10:55,331,212...55,335,530

G

carbohydrate sulfotransferase 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHST11 mRNA

NCBI chr 7:20,524,535...20,743,008
Ensembl chr 7:20,528,100...20,743,111

G

component of inhibitor of nuclear factor kappa B kinase complex

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CHUK protein modified form
notoginsenoside R1 inhibits the reaction [Dextran Sulfate results in increased expression of CHUK protein modified form]

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

creatine kinase B

decreases expression

Dextran Sulfate results in decreased expression of CKB protein

NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315

G

creatine kinase, M-type

decreases expression

Dextran Sulfate results in decreased expression of CKM protein

NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720

G

chloride channel accessory 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCA1 mRNA

NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369

G

chloride channel accessory 4

increases expression

Dextran Sulfate results in increased expression of CLCA4 mRNA

NCBI chr 2:233,883,625...233,904,993
Ensembl chr 2:233,883,851...233,903,089

G

chloride voltage-gated channel 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN2 mRNA

NCBI chr11:80,197,741...80,211,657
Ensembl chr11:80,198,153...80,211,657

G

chloride voltage-gated channel 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN3 mRNA

NCBI chr16:29,127,152...29,200,133
Ensembl chr16:29,127,419...29,200,119

G

claudin 1

multiple interactions
increases expression
decreases expression

7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN1 protein]; [(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; [SB 203580 co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein; biochanin A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]; hydroxysafflor yellow A inhibits the reaction [Dextran Sulfate results in decreased expression of CLDN1 protein]

PMID:27920472 PMID:36543318 PMID:37001609 PMID:38648921

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

claudin 11

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CLDN11 mRNA

NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050

G

claudin 2

multiple interactions
increases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; 7-hydroxyl-1-methylindole-3-acetonitrile inhibits the reaction [Dextran Sulfate results in increased expression of CLDN2 protein]; [Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of CLDN2 mRNA
Dextran Sulfate results in increased expression of CLDN2 mRNA; Dextran Sulfate results in increased expression of CLDN2 protein

PMID:26271895 PMID:29680209 PMID:36543318

NCBI chr X:103,459,870...103,473,794
Ensembl chr X:103,459,780...103,474,838

G

C-type lectin domain containing 10A

increases expression

Dextran Sulfate results in increased expression of CLEC10A mRNA

NCBI chr10:54,876,244...54,880,439
Ensembl chr10:54,876,260...54,880,435

G

chloride intracellular channel 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CLIC1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CLIC1 protein

NCBI chr20:3,764,867...3,773,711
Ensembl chr20:3,761,461...3,773,712

G

chymase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CMA1 mRNA

NCBI chr15:29,417,451...29,420,233
Ensembl chr15:29,417,451...29,420,233

G

cytidine monophosphate N-acetylneuraminic acid synthetase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CMAS mRNA

NCBI chr 4:175,718,808...175,737,128
Ensembl chr 4:175,718,808...175,737,125

G

cytidine/uridine monophosphate kinase 1

decreases expression

Dextran Sulfate results in decreased expression of CMPK1 protein

NCBI chr 5:128,480,301...128,507,830
Ensembl chr 5:128,480,301...128,507,830

G

cyclic nucleotide gated channel subunit alpha 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNGA4 mRNA

NCBI chr 1:159,752,357...159,756,369
Ensembl chr 1:159,752,357...159,756,375

G

calponin 2

decreases expression

Dextran Sulfate results in decreased expression of CNN2 protein

NCBI chr 7:9,712,505...9,719,678
Ensembl chr 7:9,712,516...9,719,656

G

cannabinoid receptor 1

decreases response to substance
multiple interactions
increases expression

CNR1 results in decreased susceptibility to Dextran Sulfate
SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]; Serotonin inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein]

PMID:15085199 PMID:27920472 PMID:30611738

NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099

G

cannabinoid receptor 2

multiple interactions
increases response to substance
affects response to substance
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CNR2 mRNA; CNR2 gene mutant form promotes the reaction [Dextran Sulfate results in increased secretion of MPO protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in decreased expression of SQSTM1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of and results in increased secretion of IL1B protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of BECN1 protein]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of IL1B mRNA]; CNR2 protein affects the reaction [[Dextran Sulfate co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of MTOR protein]; CNR2 protein affects the reaction [Dextran Sulfate results in decreased phosphorylation of RPS6KB1 protein]; CNR2 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR2 protein]
CNR2 gene mutant form results in increased susceptibility to Dextran Sulfate
CNR2 protein affects the susceptibility to Dextran Sulfate

PMID:27611972 PMID:27920472 PMID:29950665 PMID:30102254 PMID:32942172

NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548

G

ciliary neurotrophic factor receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTFR mRNA

NCBI chr 5:56,823,448...56,861,049
Ensembl chr 5:56,823,965...56,841,392

G

contactin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTN1 mRNA

NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541

G

component of oligomeric golgi complex 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COG1 protein]

NCBI chr10:98,695,481...98,708,495
Ensembl chr10:98,695,423...98,709,292

G

collagen type XI alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL11A1 mRNA

NCBI chr 2:201,820,715...202,013,853
Ensembl chr 2:201,820,715...202,013,853

G

collagen type XIV alpha 1 chain

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL14A1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of COL14A1 protein]

PMID:29950665 PMID:32272095

NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:86,722,094...86,937,214

G

collagen type XVI alpha 1 chain

increases expression

Dextran Sulfate results in increased expression of COL16A1 mRNA

NCBI chr 5:142,388,376...142,442,825
Ensembl chr 5:142,388,426...142,442,825

G

collagen type XVIII alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL18A1 mRNA

NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593

G

collagen type I alpha 1 chain

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL1A1 mRNA
Dextran Sulfate results in decreased expression of COL1A1 mRNA

PMID:29950665 PMID:35093514

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

decreases expression

Dextran Sulfate results in decreased expression of COL1A2 mRNA

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

collagen type XXII alpha 1 chain

increases expression

Dextran Sulfate results in increased expression of COL22A1 mRNA

NCBI chr 7:103,730,939...103,968,452
Ensembl chr 7:103,731,037...103,968,462

G

collagen type XXIII alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL23A1 mRNA

NCBI chr10:35,549,090...35,839,152
Ensembl chr10:35,549,113...35,836,314

G

collagen type XXVIII alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL28A1 mRNA

NCBI chr 4:36,069,980...36,223,128
Ensembl chr 4:36,069,970...36,223,220

G

collagen type III alpha 1 chain

decreases expression

Dextran Sulfate results in decreased expression of COL3A1 mRNA

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

collagen type IV alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A1 mRNA

NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412

G

collagen type IV alpha 2 chain

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A2 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL4A2 protein]

PMID:29950665 PMID:32272095

NCBI chr16:78,047,591...78,183,360
Ensembl chr16:78,047,602...78,183,839

G

collagen type V alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A1 mRNA

NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588

G

collagen type V alpha 2 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A2 mRNA

NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:47,448,736...47,598,154

G

collagen type VI alpha 1 chain

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A1 protein]
Dextran Sulfate results in decreased expression of COL6A1 mRNA; Dextran Sulfate results in decreased expression of COL6A1 protein

PMID:32272095 PMID:35093514

NCBI chr20:11,906,105...11,924,599
Ensembl chr20:11,905,957...11,924,597

G

collagen type VI alpha 2 chain

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of COL6A2 mRNA; Dextran Sulfate results in decreased expression of COL6A2 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of COL6A2 protein]

PMID:32272095 PMID:35093514

NCBI chr20:12,021,676...12,049,425
Ensembl chr20:12,021,767...12,057,564

G

collagen type VIII alpha 1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL8A1 mRNA

NCBI chr11:42,776,851...42,906,432
Ensembl chr11:42,777,628...42,906,424

G

coronin 1A

decreases expression

Dextran Sulfate results in decreased expression of CORO1A protein

NCBI chr 1:181,295,561...181,300,566
Ensembl chr 1:181,295,562...181,300,534

G

coronin 1C

decreases expression

Dextran Sulfate results in decreased expression of CORO1C protein

NCBI chr12:42,713,024...42,785,179
Ensembl chr12:42,712,991...42,785,179

G

coactosin-like F-actin binding protein 1

decreases expression

Dextran Sulfate results in decreased expression of COTL1 protein

NCBI chr19:47,871,689...47,906,010
Ensembl chr19:47,871,694...47,911,689

G

cytochrome c oxidase subunit 5B

increases expression

Dextran Sulfate results in increased expression of COX5B mRNA

NCBI chr 9:38,921,980...38,923,806
Ensembl chr 9:38,921,967...38,925,052

G

ceruloplasmin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CP mRNA

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

carboxypeptidase A1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CPA1 mRNA

NCBI chr 4:59,257,417...59,263,544
Ensembl chr 4:59,257,417...59,263,544

G

carboxypeptidase B2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CPB2 mRNA

NCBI chr15:50,557,722...50,606,569
Ensembl chr15:50,557,717...50,606,556

G

complement C3d receptor 2

increases expression

Dextran Sulfate results in increased expression of CR2 mRNA

NCBI chr13:106,678,579...106,716,595
Ensembl chr13:106,685,413...106,716,235

G

capping protein inhibiting regulator of actin dynamics

increases expression

Dextran Sulfate results in increased expression of CRACD mRNA

NCBI chr14:31,284,066...31,520,103
Ensembl chr14:31,284,184...31,522,431

G

corticotropin releasing hormone receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CRHR1 mRNA

NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481

G

corticotropin releasing hormone receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRHR2 mRNA

NCBI chr 4:84,222,897...84,265,924
Ensembl chr 4:84,224,002...84,265,904

G

cysteine-rich secretory protein 1

decreases expression

Dextran Sulfate results in decreased expression of CRISP1 protein

NCBI chr 9:20,741,775...20,768,796
Ensembl chr 9:20,741,777...20,768,796

G

cartilage associated protein

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRTAP mRNA

NCBI chr 8:114,047,929...114,067,636
Ensembl chr 8:114,047,933...114,067,631

G

colony stimulating factor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF1 mRNA

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

colony stimulating factor 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CSF2 mRNA; Dextran Sulfate results in increased expression of CSF2 protein
[Ampicillin co-treated with Vancomycin co-treated with Neomycin co-treated with Metronidazole] inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2 mRNA; Polymyxin B inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 protein]; Rutin inhibits the reaction [Dextran Sulfate results in increased expression of CSF2 mRNA]; TLR4 protein affects the reaction [Dextran Sulfate results in increased expression of CSF2 protein]

PMID:15652231 PMID:29950665 PMID:31442584

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

colony stimulating factor 2 receptor subunit beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2RB2 mRNA

NCBI chr 7:109,876,919...109,901,589
Ensembl chr 7:109,886,425...109,904,157

G

colony stimulating factor 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CSF3 mRNA
Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CSF3 mRNA]

NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603

G

colony stimulating factor 3 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CSF3R mRNA

NCBI chr 5:138,298,605...138,318,224
Ensembl chr 5:138,301,506...138,317,881

G

catenin beta 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of CTNNB1 protein
[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased expression of CTNNB1 protein; [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate] results in increased mutagenesis of CTNNB1 gene; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein]; CTNNB1 gene mutant form results in increased susceptibility to [2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Dextran Sulfate]

PMID:15459021 PMID:16049979 PMID:27664423 PMID:31715269

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

CTP synthase 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of CTPS1 protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTPS1 protein]

NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:134,125,025...134,154,180

G

cathepsin C

decreases expression

Dextran Sulfate results in decreased expression of CTSC mRNA

NCBI chr 1:142,028,386...142,059,841
Ensembl chr 1:142,028,392...142,060,387

G

cathepsin D

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of CTSD protein]

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cathepsin K

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSK mRNA

NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550

G

cathepsin L

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of CTSL protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSL mRNA

PMID:29950665 PMID:35999755

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

cathepsin S

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of CTSS protein]

NCBI chr 2:183,086,437...183,114,483
Ensembl chr 2:183,086,437...183,114,483

G

cubilin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CUBN mRNA

NCBI chr17:76,385,046...76,593,133
Ensembl chr17:76,385,060...76,593,231

G

C-X3-C motif chemokine receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CX3CR1 mRNA

NCBI chr 8:119,785,726...119,799,431
Ensembl chr 8:119,782,595...119,800,014

G

CXADR, Ig-like cell adhesion molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXADR mRNA

NCBI chr11:16,982,864...17,030,078
Ensembl chr11:16,982,860...17,030,046

G

C-X-C motif chemokine ligand 10

multiple interactions

[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA]

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

C-X-C motif chemokine ligand 12

decreases expression

Dextran Sulfate results in decreased expression of CXCL12 mRNA

NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168

G

C-X-C motif chemokine ligand 13

increases expression

Dextran Sulfate results in increased expression of CXCL13 mRNA

PMID:23894361 PMID:35093514

NCBI chr14:13,608,894...13,613,965
Ensembl chr14:13,608,902...13,613,933

G

C-X-C motif chemokine ligand 14

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL14 mRNA

NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839

G

C-X-C motif chemokine ligand 2

multiple interactions
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; Qingdai compound inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]
Dextran Sulfate results in increased expression of CXCL2 mRNA; Dextran Sulfate results in increased expression of CXCL2 protein

PMID:21724996 PMID:32033881 PMID:34998820 PMID:36519841

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

C-X-C motif chemokine ligand 3

multiple interactions
increases secretion
increases expression

17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXCL1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL1 mRNA; AHR gene mutant form promotes the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; Benzo(a)pyrene inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 mRNA]; resolvin D1 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; resolvin D2 inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased secretion of CXCL1 protein]
Dextran Sulfate results in increased expression of CXCL1 mRNA; Dextran Sulfate results in increased expression of CXCL1 protein

PMID:19645018 PMID:20079348 PMID:21724996 PMID:21858153 PMID:29950665 More...

NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511

G

C-X-C motif chemokine ligand 9

increases expression

Dextran Sulfate results in increased expression of CXCL9 mRNA

NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435

G

C-X-C motif chemokine receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCR2 mRNA

NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425

G

cytochrome b-245 alpha chain

increases expression

Dextran Sulfate results in increased expression of CYBA protein

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

cytochrome b-245 beta chain

increases expression

Dextran Sulfate results in increased expression of CYBB mRNA; Dextran Sulfate results in increased expression of CYBB protein

PMID:20637373 PMID:23894361

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytoplasmic FMR1 interacting protein 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP1 mRNA

NCBI chr 1:106,710,924...106,799,393
Ensembl chr 1:106,711,016...106,799,386

G

cytoplasmic FMR1 interacting protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP2 mRNA

NCBI chr10:30,621,318...30,741,113
Ensembl chr10:30,621,318...30,741,113

G

cytochrome P450, family 11, subfamily a, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP11A1 mRNA

NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338

G

cytochrome P450, family 17, subfamily a, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP17A1 mRNA

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases expression

6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 mRNA]; 6-formylindolo(3,2-b)carbazole inhibits the reaction [Dextran Sulfate results in decreased expression of CYP1A1 protein]; Dextran Sulfate inhibits the reaction [Benzo(a)pyrene results in increased expression of CYP1A1 mRNA]
Dextran Sulfate results in decreased expression of CYP1A1 mRNA; Dextran Sulfate results in decreased expression of CYP1A1 protein

PMID:29680209 PMID:34998820

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
decreases activity

[Dextran Sulfate results in decreased activity of CYP1A2 protein] which results in decreased chemical synthesis of Acetaminophen

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 24, subfamily a, polypeptide 1

increases expression

Dextran Sulfate results in increased expression of CYP24A1 protein

NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383

G

cytochrome P450, family 26, subfamily b, polypeptide 1

decreases expression

Dextran Sulfate results in decreased expression of CYP26B1 mRNA

NCBI chr 4:117,041,808...117,058,628
Ensembl chr 4:117,041,808...117,058,628

G

cytochrome P450, family 27, subfamily b, polypeptide 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP27B1 mRNA
Dextran Sulfate results in decreased expression of CYP27B1 protein

PMID:29950665 PMID:38588969

NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241

G

cytochrome P450, family 2, subfamily b, polypeptide 1

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of CYP2B1 protein
[Dextran Sulfate results in decreased activity of CYP2B1 protein] which results in decreased chemical synthesis of hydroxybupropion

NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052

G

cytochrome P450, family 2, subfamily b, polypeptide 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2B13 mRNA

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2B10 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily c, polypeptide 24

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C55 mRNA

NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:236,873,967...236,936,238

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C29 mRNA

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily c, polypeptide 66

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C66 mRNA

NCBI chr 1:237,078,517...237,169,841
Ensembl chr 1:237,078,517...237,169,650

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity
multiple interactions

Dextran Sulfate results in decreased activity of CYP2E1 protein
[Dextran Sulfate results in decreased activity of CYP2E1 protein] which results in decreased chemical synthesis of 6-hydroxychlorzoxazone

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 2, subfamily j, polypeptide 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J9 mRNA

NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794

G

cytochrome P450, family 2, subfamily r, polypeptide 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2R1 mRNA; Cholecalciferol inhibits the reaction [Dextran Sulfate results in decreased expression of CYP2R1 protein]

PMID:29950665 PMID:38588969

NCBI chr 1:168,749,302...168,798,079
Ensembl chr 1:168,751,038...168,797,759

G

cytochrome P450, family 2, subfamily s, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2S1 mRNA

NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:81,310,451...81,325,303

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A11 mRNA

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450, family 4, subfamily b, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4B1 mRNA

NCBI chr 5:129,139,019...129,176,860
Ensembl chr 5:129,139,038...129,156,348

G

cytochrome P450, family 4, subfamily f, polypeptide 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F14 mRNA

NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,010,852...12,022,046

G

cytochrome P450, family 4, subfamily f, polypeptide 39

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP4F39 mRNA

NCBI chr 7:11,426,806...11,505,553
Ensembl chr 7:11,433,371...11,536,181

G

cytochrome P450 family 7 subfamily A member 1

decreases expression

Dextran Sulfate results in decreased expression of CYP7A1 mRNA

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 7 subfamily B member 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP7B1 mRNA

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

dihydrolipoamide branched chain transacylase E2

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of DBT protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of DBT protein]

NCBI chr 2:204,481,744...204,510,612
Ensembl chr 2:204,481,737...204,510,609

G

decorin

multiple interactions
increases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DCN mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DCN protein]

PMID:29950665 PMID:32272095

NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270

G

discoidin domain receptor tyrosine kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DDR2 mRNA

NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363

G

DEPP autophagy regulator 1

increases expression

Dextran Sulfate results in increased expression of DEPP1 mRNA

NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542

G

derlin 3

increases expression

Dextran Sulfate results in increased expression of DERL3 mRNA

NCBI chr20:12,754,490...12,768,454
Ensembl chr20:12,763,543...12,767,027

G

diacylglycerol kinase, beta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DGKB mRNA

NCBI chr 6:54,640,948...55,397,210
Ensembl chr 6:54,641,614...55,397,043

G

diacylglycerol kinase, iota

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DGKI mRNA

NCBI chr 4:65,410,878...65,872,733
Ensembl chr 4:65,420,108...65,872,733

G

24-dehydrocholesterol reductase

decreases expression

Dextran Sulfate results in decreased expression of DHCR24 mRNA

NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137

G

dehydrogenase/reductase 9

increases expression

Dextran Sulfate results in increased expression of DHRS9 mRNA

NCBI chr 3:54,147,834...54,170,052
Ensembl chr 3:54,147,803...54,220,241

G

dehydrogenase/reductase X-linked

increases expression

Dextran Sulfate results in increased expression of DHRSX mRNA

NCBI chr12:16,299,768...16,304,553
Ensembl chr12:16,299,808...16,304,552

G

dickkopf WNT signaling pathway inhibitor 2

multiple interactions

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA]

NCBI chr 2:220,568,338...220,660,225
Ensembl chr 2:220,568,338...220,660,225

G

delta like non-canonical Notch ligand 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DLK1 mRNA

NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:128,410,316...128,417,522

G

DM1 protein kinase

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of DMPK mRNA

NCBI chr 1:78,730,255...78,740,585
Ensembl chr 1:78,730,275...78,740,593

G

DMRT-like family A1

decreases expression

Dextran Sulfate results in decreased expression of DMRTA1 mRNA

NCBI chr 5:104,415,893...104,422,433
Ensembl chr 5:104,415,893...104,422,433

G

DM1 locus, WD repeat containing

increases expression

Dextran Sulfate results in increased expression of DMWD mRNA

NCBI chr 1:78,722,436...78,729,224
Ensembl chr 1:78,722,330...78,740,593

G

DnaJ heat shock protein family (Hsp40) member C10

increases expression
multiple interactions

Dextran Sulfate results in increased expression of DNAJC10 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DNAJC10 protein]

NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719

G

dynamin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM1 mRNA

NCBI chr 3:15,604,782...15,648,654
Ensembl chr 3:15,604,784...15,648,538

G

dynamin 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM3 mRNA

NCBI chr13:74,359,043...74,838,135
Ensembl chr13:74,359,213...74,838,108

G

docking protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DOK2 mRNA

NCBI chr15:45,826,984...45,841,409
Ensembl chr15:45,827,398...45,841,402

G

dipeptidase 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of DPEP1 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP1 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of DPEP1 protein]

PMID:32272095 PMID:35999755

NCBI chr19:51,209,831...51,237,004
Ensembl chr19:51,219,660...51,235,257

G

dipeptidase 2

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of DPEP2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DPEP2 mRNA

PMID:29950665 PMID:35999755

NCBI chr19:33,883,557...33,896,487
Ensembl chr19:33,885,478...33,891,954

G

dihydropyrimidine dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DPYD mRNA

NCBI chr 2:206,609,043...207,474,982
Ensembl chr 2:206,609,122...207,474,982

G

Dr1 associated protein 1

increases expression

Dextran Sulfate results in increased expression of DRAP1 mRNA

NCBI chr 1:202,731,775...202,734,468
Ensembl chr 1:202,731,788...202,734,425

G

dopamine receptor D4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD4 mRNA

NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553

G

dopamine receptor D5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD5 mRNA

NCBI chr14:72,487,950...72,491,050
Ensembl chr14:72,489,347...72,490,774

G

deltex E3 ubiquitin ligase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DTX1 mRNA

NCBI chr12:35,849,647...35,880,835
Ensembl chr12:35,849,617...35,880,838

G

dual oxidase maturation factor 2

increases expression

Dextran Sulfate results in increased expression of DUOXA2 mRNA

NCBI chr 3:109,245,337...109,249,055
Ensembl chr 3:109,245,476...109,248,968

G

dual specificity phosphatase 1

multiple interactions
increases expression

DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of IL6 protein]]; DUSP1 protein affects the reaction [Resveratrol affects the reaction [Dextran Sulfate affects the expression of TNF protein]]; DUSP1 protein affects the reaction [Resveratrol inhibits the reaction [Dextran Sulfate results in increased expression of PTGS2 protein]]; DUSP1 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]
Dextran Sulfate results in increased expression of DUSP1 mRNA

PMID:30844440 PMID:35093514

NCBI chr10:16,680,478...16,683,275

G

enoyl-CoA delta isomerase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ECI1 mRNA

NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061

G

Ecm29 proteasome adaptor and scaffold

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ECPAS protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ECPAS protein]

NCBI chr 5:73,601,745...73,714,026
Ensembl chr 5:73,604,533...73,713,860

G

ectodysplasin-A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA mRNA

NCBI chr X:65,078,454...65,480,172
Ensembl chr X:65,078,673...65,480,172

G

ectodysplasin A2 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA2R mRNA

NCBI chr X:62,224,763...62,269,333
Ensembl chr X:62,228,229...62,269,268

G

endothelial differentiation-related factor 1

increases expression

Dextran Sulfate results in increased expression of EDF1 mRNA

NCBI chr 3:8,377,058...8,381,363
Ensembl chr 3:8,366,613...8,381,363

G

endothelin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDN1 mRNA

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

endothelin 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of EDN2 protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EDN2 mRNA

PMID:16216902 PMID:29950665

NCBI chr 5:133,751,316...133,756,814
Ensembl chr 5:133,751,217...133,756,814

G

endothelin receptor type A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDNRA mRNA

NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049

G

eukaryotic translation elongation factor 1 gamma

decreases expression

Dextran Sulfate results in decreased expression of EEF1G protein

NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382

G

EGF containing fibulin extracellular matrix protein 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EFEMP2 mRNA

NCBI chr 1:202,781,692...202,789,784
Ensembl chr 1:202,781,665...202,789,414

G

EF-hand domain family, member D2

increases expression

Dextran Sulfate results in increased expression of EFHD2 mRNA

NCBI chr 5:154,160,945...154,176,980
Ensembl chr 5:154,160,946...154,176,980

G

ephrin A1

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of EFNA1 mRNA

NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866

G

egl-9 family hypoxia-inducible factor 2

increases expression

Dextran Sulfate results in increased expression of EGLN2 mRNA

NCBI chr 1:82,451,554...82,459,809
Ensembl chr 1:82,451,555...82,459,751

G

EH-domain containing 1

decreases expression

Dextran Sulfate results in decreased expression of EHD1 protein

NCBI chr 1:203,579,850...203,602,226
Ensembl chr 1:203,579,869...203,602,212

G

EH-domain containing 4

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of EHD4 protein
Dextran Sulfate results in decreased expression of EHD4 protein

NCBI chr 3:107,058,191...107,121,985
Ensembl chr 3:107,058,958...107,122,002

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EHHADH mRNA

NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188

G

euchromatic histone lysine methyltransferase 2

increases expression

Dextran Sulfate results in increased expression of EHMT2 mRNA

NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547

G

eukaryotic translation initiation factor 2-alpha kinase 2

multiple interactions
increases phosphorylation

EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased activity of CASP3 protein]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of IL6 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased expression of NOS2 mRNA]; EIF2AK2 protein affects the reaction [Dextran Sulfate results in increased phosphorylation of RELA protein]; GW 506033X inhibits the reaction [Dextran Sulfate results in increased phosphorylation of EIF2AK2 protein]

NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971

G

eukaryotic translation initiation factor 3, subunit A

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of EIF3A mRNA

NCBI chr 1:259,902,767...259,932,976
Ensembl chr 1:259,902,680...259,932,976

G

eukaryotic translation initiation factor 5A

decreases expression

Dextran Sulfate results in decreased expression of EIF5A protein

NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656

G

eukaryotic translation initiation factor 5B

increases expression

Dextran Sulfate results in increased expression of EIF5B mRNA

NCBI chr 9:40,222,769...40,277,482
Ensembl chr 9:40,222,898...40,277,482

G

elastase, neutrophil expressed

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELANE mRNA

NCBI chr 7:9,817,251...9,819,174
Ensembl chr 7:9,817,252...9,819,100

G

engulfment and cell motility 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELMO2 mRNA

NCBI chr 3:154,023,661...154,061,259
Ensembl chr 3:154,023,661...154,061,185

G

ER membrane protein complex subunit 2

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of EMC2 protein]

NCBI chr 7:74,587,196...74,624,163
Ensembl chr 7:74,587,175...74,625,189

G

epithelial membrane protein 2

decreases expression

Dextran Sulfate results in decreased expression of EMP2 mRNA

NCBI chr10:5,360,073...5,394,734
Ensembl chr10:5,360,073...5,394,733

G

endoglin

decreases expression

Dextran Sulfate results in decreased expression of ENG mRNA

NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230

G

enolase 1

decreases expression

Dextran Sulfate results in decreased expression of ENO1 protein

NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336

G

enolase 3

multiple interactions
decreases expression

[Dextran Sulfate co-treated with bisphenol A] results in increased expression of ENO3 protein; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of ENO3 protein]

PMID:32272095 PMID:35999755

NCBI chr10:55,370,531...55,375,921
Ensembl chr10:55,366,975...55,375,921

G

glutamyl aminopeptidase

multiple interactions
increases expression

Erianin inhibits the reaction [Dextran Sulfate results in increased expression of ENPEP protein]

NCBI chr 2:217,781,985...217,851,947
Ensembl chr 2:217,782,005...217,851,947

G

ectonucleoside triphosphate diphosphohydrolase 5

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in decreased expression of ENTPD5 mRNA

NCBI chr 6:104,019,095...104,055,311
Ensembl chr 6:104,019,185...104,055,530

G

E1A binding protein p300

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EP300 mRNA

NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

epoxide hydrolase 1

decreases expression

Dextran Sulfate results in decreased expression of EPHX1 mRNA

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB2 mRNA

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

erb-b2 receptor tyrosine kinase 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB3 mRNA

NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525

G

erb-b2 receptor tyrosine kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ERBB4 mRNA

NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595

G

epiregulin

decreases response to substance
increases expression

EREG protein results in decreased susceptibility to Dextran Sulfate
dextran sodium sulfate increases expression of Ereg protein in colonic mucosa

CTD
RGD

PMID:15456865 PMID:20498653

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

ERBB receptor feedback inhibitor 1

increases expression

Dextran Sulfate results in increased expression of ERRFI1 mRNA

NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282

G

endothelial cell adhesion molecule

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESAM mRNA

NCBI chr 8:37,238,228...37,249,217
Ensembl chr 8:37,238,287...37,249,215

G

estrogen receptor 1

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of ESR1 mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESR1 mRNA

PMID:29950665 PMID:30270565

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen receptor 2

multiple interactions

Dextran Sulfate promotes the reaction [Zearalenone results in increased expression of ESR2 mRNA]

NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919

G

Enah/Vasp-like

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EVL mRNA

NCBI chr 6:127,473,119...127,594,342
Ensembl chr 6:127,474,543...127,594,344

G

EWS RNA-binding protein 1

increases expression

Dextran Sulfate results in increased expression of EWSR1 mRNA

NCBI chr14:79,965,365...79,994,108
Ensembl chr14:79,965,368...79,994,544

G

coagulation factor X

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F10 mRNA

NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141

G

coagulation factor XI

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of F11 protein

NCBI chr16:46,987,988...47,009,015
Ensembl chr16:46,986,107...47,008,437

G

coagulation factor XIII A1 chain

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F13A1 mRNA

NCBI chr17:27,815,723...27,992,494
Ensembl chr17:27,815,702...27,992,700

G

coagulation factor II (thrombin) receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F2R mRNA

NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870

G

F2R like trypsin receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of F2RL1 mRNA

NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226

G

coagulation factor V

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F5 mRNA

NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317

G

fatty acid amide hydrolase

multiple interactions

[Serotonin co-treated with Dextran Sulfate] results in decreased expression of FAAH protein

NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677

G

fatty acid binding protein 4

multiple interactions
increases expression

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of FABP4 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FABP4 protein]

PMID:26271895 PMID:32272095

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

fatty acid binding protein 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FABP6 mRNA

NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282

G

fatty acid desaturase 1

decreases expression

Dextran Sulfate results in decreased expression of FADS1 mRNA

NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734

G

fatty acid desaturase 2

decreases expression

Dextran Sulfate results in decreased expression of FADS2 mRNA

NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789

G

family with sequence similarity 229, member A

increases expression

Dextran Sulfate results in increased expression of FAM229A mRNA

NCBI chr 5:141,829,716...141,830,705
Ensembl chr 5:141,828,664...141,830,705

G

family with sequence similarity 50, member B

increases expression

Dextran Sulfate results in increased expression of FAM50B mRNA

NCBI chr17:30,174,431...30,193,627
Ensembl chr17:30,174,411...30,193,615

G

family with sequence similarity 98, member B

increases expression

Dextran Sulfate results in increased expression of FAM98B mRNA

NCBI chr 3:104,134,803...104,164,249
Ensembl chr 3:104,134,824...104,163,704

G

FAU ubiquitin like and ribosomal protein S30 fusion

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FAU protein]

NCBI chr 1:203,350,226...203,351,741
Ensembl chr 1:203,350,189...203,351,742

G

fibulin 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN2 mRNA

NCBI chr 4:123,704,289...123,763,857
Ensembl chr 4:123,704,373...123,763,948

G

fibulin 5

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN5 mRNA
Dextran Sulfate results in decreased expression of FBLN5 mRNA

PMID:29950665 PMID:35093514

NCBI chr 6:120,899,219...120,977,829
Ensembl chr 6:120,899,224...120,977,755

G

fibrillin 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBN1 mRNA; Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FBN1 protein]

PMID:29950665 PMID:32272095

NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:112,554,925...112,750,889

G

F-box protein 2

increases expression

Dextran Sulfate results in increased expression of FBXO2 mRNA

NCBI chr 5:158,592,926...158,598,355
Ensembl chr 5:158,592,925...158,598,355

G

Fc epsilon receptor Ig

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCER1G mRNA

NCBI chr13:83,649,447...83,654,248
Ensembl chr13:83,649,449...83,671,443

G

Fc gamma receptor 1A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR1 mRNA

NCBI chr 2:183,851,075...183,860,077
Ensembl chr 2:183,851,077...183,859,994

G

Fc gamma receptor 2A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR3 mRNA

NCBI chr13:83,280,782...83,297,535
Ensembl chr13:83,280,784...83,295,967

G

Fc gamma receptor 2B

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR2B mRNA

NCBI chr13:83,191,253...83,207,778
Ensembl chr13:83,193,163...83,207,778

G

Fc gamma receptor 3A

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR4 mRNA

NCBI chr13:83,249,905...83,259,921
Ensembl chr13:83,249,872...83,259,921

G

fucose kinase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FCSK mRNA

NCBI chr19:38,849,130...38,874,497
Ensembl chr19:38,854,762...38,874,418

G

ferredoxin 1

multiple interactions
decreases expression

Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of FDX1 protein]

NCBI chr 8:52,268,536...52,287,344
Ensembl chr 8:52,268,536...52,287,414

G

ferredoxin reductase

decreases expression

Dextran Sulfate results in decreased expression of FDXR mRNA

NCBI chr10:100,507,863...100,516,649
Ensembl chr10:100,507,865...100,516,658

G

FERM domain containing kindlin 3

increases expression
decreases expression
multiple interactions

Dextran Sulfate results in increased expression of FERMT3 protein
Dextran Sulfate results in decreased expression of FERMT3 protein
[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FERMT3 protein; Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FERMT3 protein]

PMID:32272095 PMID:35999755

NCBI chr 1:204,189,483...204,207,683
Ensembl chr 1:204,189,484...204,207,587

G

free fatty acid receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR2 mRNA

NCBI chr 1:86,071,855...86,075,049
Ensembl chr 1:86,072,184...86,075,033

G

free fatty acid receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR4 mRNA

NCBI chr 1:235,873,576...235,891,597
Ensembl chr 1:235,873,576...235,891,597

G

fibroblast growth factor 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF18 mRNA

NCBI chr10:17,706,011...17,737,702
Ensembl chr10:17,706,174...17,736,818

G

fibroblast growth factor 19

multiple interactions

Dextran Sulfate results in increased expression of and results in increased secretion of FGF15 protein

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

fibroblast growth factor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF2 mRNA

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

fibroblast growth factor 23

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF23 mRNA

NCBI chr 4:159,914,267...159,923,821
Ensembl chr 4:159,914,272...159,923,821

G

fibroblast growth factor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF8 mRNA

NCBI chr 1:244,584,477...244,590,578
Ensembl chr 1:244,584,652...244,590,359

G

fibroblast growth factor 9

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF9 mRNA

NCBI chr15:32,208,993...32,254,952
Ensembl chr15:32,210,074...32,253,309

G

Fibroblast growth factor receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGFR1 mRNA

NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350

G

fibroblast growth factor receptor 4

increases expression

Dextran Sulfate results in increased expression of FGFR4 mRNA

NCBI chr17:9,461,541...9,476,268
Ensembl chr17:9,461,547...9,476,242

G

fibrinogen-like 1

increases expression

Dextran Sulfate results in increased expression of FGL1 protein

NCBI chr16:51,120,652...51,150,907
Ensembl chr16:51,120,694...51,151,093

G

four and a half LIM domains 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FHL1 protein

NCBI chr X:134,555,399...134,614,930
Ensembl chr X:134,555,479...134,614,928

G

four and a half LIM domains 2

decreases expression

Dextran Sulfate results in decreased expression of FHL2 mRNA

NCBI chr 9:45,388,979...45,462,421
Ensembl chr 9:45,388,981...45,431,192

G

four and a half LIM domains 3

increases expression
multiple interactions

Dextran Sulfate results in increased expression of FHL3 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FHL3 protein]

NCBI chr 5:136,953,947...136,961,317
Ensembl chr 5:136,950,411...136,961,317

G

filamin A

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of FLNA protein

NCBI chr X:152,007,758...152,034,266
Ensembl chr X:152,007,758...152,031,052

G

flotillin 2

increases expression
multiple interactions

Dextran Sulfate results in increased expression of FLOT2 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of FLOT2 protein]

NCBI chr10:62,926,047...62,947,759
Ensembl chr10:62,920,665...62,947,756

G

Fms related receptor tyrosine kinase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT1 mRNA

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

Fms related receptor tyrosine kinase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT4 mRNA

NCBI chr10:33,913,725...33,954,770
Ensembl chr10:33,913,608...33,954,770

G

flavin containing dimethylaniline monoxygenase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMO1 mRNA

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647

G

fibromodulin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMOD mRNA

NCBI chr13:45,493,517...45,504,134
Ensembl chr13:45,493,517...45,504,133

G

fibronectin 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FN1 mRNA

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions
increases expression

Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]; GRK6 mutant form promotes the reaction [Dextran Sulfate promotes the reaction [Capsaicin results in increased expression of FOS protein]]
Dextran Sulfate results in increased expression of FOS mRNA

PMID:18687398 PMID:35093514

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

FOS like 1, AP-1 transcription factor subunit

increases expression

Dextran Sulfate results in increased expression of FOSL1 protein

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

forkhead box A2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA2 mRNA

NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:135,470,131...135,474,326

G

forkhead box A3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA3 mRNA

NCBI chr 1:78,662,067...78,672,321
Ensembl chr 1:78,662,431...78,672,155

G

forkhead box O1

increases expression

Dextran Sulfate results in increased expression of FOXO1 mRNA; Dextran Sulfate results in increased expression of FOXO1 protein

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

forkhead box O3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXO3 mRNA

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

forkhead box O4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FOXO4 mRNA

NCBI chr X:66,385,241...66,392,115
Ensembl chr X:66,385,558...66,392,115

G

forkhead box P3

increases methylation
increases expression
multiple interactions

Dextran Sulfate results in increased methylation of FOXP3 gene
Dextran Sulfate results in increased expression of FOXP3 mRNA
kappa-casein glycomacropeptide inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA]
Chlorpyrifos inhibits the reaction [Dextran Sulfate results in increased expression of FOXP3 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Dextran Sulfate results in increased methylation of FOXP3 gene]

PMID:20881082 PMID:21858153 PMID:31807802 PMID:34998820

NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838

G

fucose-1-phosphate guanylyltransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPGT mRNA

NCBI chr 2:244,099,031...244,119,967
Ensembl chr 2:244,099,076...244,119,899

G

formyl peptide receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR1 mRNA

NCBI chr 1:58,745,019...58,756,776
Ensembl chr 1:58,747,246...58,756,559

G

formyl peptide receptor 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR2 mRNA

NCBI chr 1:58,776,592...58,785,227
Ensembl chr 1:58,776,752...58,786,019

G

FRAT regulator of WNT signaling pathway 2

increases expression

Dextran Sulfate results in increased expression of FRAT2 mRNA

NCBI chr 1:240,654,120...240,656,449
Ensembl chr 1:240,654,137...240,656,517

G

follicle stimulating hormone subunit beta

multiple interactions
decreases expression

gingerol inhibits the reaction [Dextran Sulfate results in decreased expression of FSHB protein]; Sulfasalazine inhibits the reaction [Dextran Sulfate results in decreased expression of FSHB protein]

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

follicle stimulating hormone receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSHR mRNA

NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785

G

follistatin

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FST mRNA

NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:46,123,439...46,130,571

G

follistatin like 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSTL3 mRNA

NCBI chr 7:9,923,574...9,929,223
Ensembl chr 7:9,923,576...9,939,639

G

Fus RNA binding protein

increases expression

Dextran Sulfate results in increased expression of FUS mRNA

NCBI chr 1:182,576,479...182,590,417
Ensembl chr 1:182,576,545...182,590,414

G

FXYD domain-containing ion transport regulator 1

multiple interactions
decreases expression

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD1 mRNA
Dextran Sulfate results in decreased expression of FXYD1 mRNA

PMID:29950665 PMID:35093514

NCBI chr 1:86,287,163...86,291,478
Ensembl chr 1:86,287,165...86,291,278

G

FXYD domain-containing ion transport regulator 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD3 mRNA

NCBI chr 1:86,305,531...86,312,455

G

FXYD domain-containing ion transport regulator 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD4 mRNA

NCBI chr 4:151,109,779...151,113,659
Ensembl chr 4:151,109,779...151,113,637

G

FYN proto-oncogene, Src family tyrosine kinase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FYN mRNA

NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911

G

frizzled class receptor 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD1 mRNA

NCBI chr 4:29,310,303...29,314,701
Ensembl chr 4:29,310,091...29,312,643
Ensembl chr 4:29,310,091...29,312,643

G

frizzled class receptor 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD4 mRNA

NCBI chr 1:143,279,934...143,288,799
Ensembl chr 1:143,280,065...143,285,724

G

frizzled class receptor 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD5 mRNA

NCBI chr 9:66,113,096...66,120,276
Ensembl chr 9:66,113,112...66,121,457

G

frizzled class receptor 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD6 mRNA

NCBI chr 7:70,055,012...70,086,781
Ensembl chr 7:70,055,068...70,086,776

G

frizzled class receptor 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD7 mRNA

NCBI chr 9:60,931,433...60,934,252
Ensembl chr 9:60,930,875...60,935,781

G

frizzled class receptor 8

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD8 mRNA

NCBI chr17:57,312,924...57,320,551
Ensembl chr17:57,314,450...57,320,650

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of G6PC1 mRNA

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

gamma-aminobutyric acid type B receptor subunit 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GABBR1 mRNA

NCBI chr20:1,464,534...1,494,114
Ensembl chr20:1,464,534...1,493,994

G

gamma-aminobutyric acid type A receptor subunit alpha 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA2 mRNA

NCBI chr14:37,097,251...37,230,030
Ensembl chr14:37,097,279...37,228,944

G

gamma-aminobutyric acid type A receptor subunit alpha 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA5 mRNA

NCBI chr 1:108,268,728...108,381,670
Ensembl chr 1:108,268,776...108,380,917

G

gamma-aminobutyric acid type A receptor subunit beta 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRB2 mRNA

NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251

G

gamma-aminobutyric acid type A receptor subunit delta

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRD mRNA

NCBI chr 5:165,958,508...165,970,407
Ensembl chr 5:165,958,484...165,970,411

G

glutamate decarboxylase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAD1 mRNA

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

UDP-galactose-4-epimerase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALE mRNA

NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:148,194,791...148,198,388

G

galactokinase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALK2 mRNA

NCBI chr 3:113,110,057...113,243,014
Ensembl chr 3:113,110,030...113,233,306

G

galactose mutarotase

increases expression

Dextran Sulfate results in increased expression of GALM mRNA

NCBI chr 6:14,837,540...14,889,484
Ensembl chr 6:14,837,548...14,889,310

G

polypeptide N-acetylgalactosaminyltransferase 10

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT10 mRNA

NCBI chr10:41,821,216...41,967,618
Ensembl chr10:41,820,158...41,967,013

G

polypeptide N-acetylgalactosaminyltransferase 12

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT12 mRNA

NCBI chr 5:61,384,575...61,413,346
Ensembl chr 5:61,384,571...61,413,354

G

polypeptide N-acetylgalactosaminyltransferase 15

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT15 mRNA

NCBI chr16:7,227,232...7,267,002
Ensembl chr16:7,227,271...7,267,014

G

polypeptide N-acetylgalactosaminyltransferase 16

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT16 mRNA

NCBI chr 6:100,168,943...100,250,718
Ensembl chr 6:100,170,306...100,250,705

G

polypeptide N-acetylgalactosaminyltransferase 18

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT18 mRNA

NCBI chr 1:165,593,180...165,904,268
Ensembl chr 1:165,593,187...165,904,268

G

polypeptide N-acetylgalactosaminyltransferase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT2 mRNA

NCBI chr19:52,213,226...52,324,816
Ensembl chr19:52,213,351...52,324,813

G

polypeptide N-acetylgalactosaminyltransferase 4

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT4 mRNA

NCBI chr 7:33,925,229...33,927,770

G

polypeptide N-acetylgalactosaminyltransferase 5

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT5 mRNA

NCBI chr 3:42,573,622...42,619,881
Ensembl chr 3:42,573,622...42,619,881

G

polypeptide N-acetylgalactosaminyltransferase 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT6 mRNA

NCBI chr 7:131,789,836...131,828,077
Ensembl chr 7:131,789,839...131,819,661

G

polypeptide N-acetylgalactosaminyltransferase 7

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT7 mRNA

NCBI chr16:32,578,643...32,703,189
Ensembl chr16:32,578,690...32,702,690

G

polypeptide N-acetylgalactosaminyltransferase-like 6

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNTL6 mRNA

NCBI chr16:31,192,880...32,443,979
Ensembl chr16:31,186,462...32,441,960

G

GAR1 ribonucleoprotein

increases expression

Dextran Sulfate results in increased expression of GAR1 mRNA

NCBI chr 2:218,375,231...218,382,509
Ensembl chr 2:218,375,353...218,382,524

G

growth arrest specific 8

increases expression

Dextran Sulfate results in increased expression of GAS8 mRNA

NCBI chr19:51,552,770...51,572,323
Ensembl chr19:51,552,816...51,572,305

G

gastrin

decreases response to substance
multiple interactions

GAST protein modified form results in decreased susceptibility to Dextran Sulfate
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAST mRNA

PMID:16618411 PMID:29950665

NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,264,832...85,267,496

G

GATA binding protein 2

multiple interactions

[Benzo(a)pyrene co-treated with Dextran Sulfate] results in increased expression of GATA2 mRNA

NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761

G

guanylate binding protein family member 6

increases expression
multiple interactions

Dextran Sulfate results in increased expression of GBP9 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GBP9 protein]

NCBI chr14:4,730,286...4,756,508
Ensembl chr14:4,730,453...4,839,062
Ensembl chr14:4,730,453...4,839,062

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLC mRNA

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLM mRNA

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glucosaminyl (N-acetyl) transferase 3, mucin type

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCNT3 mRNA

NCBI chr 8:70,689,173...70,696,476
Ensembl chr 8:70,686,844...70,699,562

G

GDP dissociation inhibitor 1

multiple interactions

[Dextran Sulfate co-treated with bisphenol A] results in decreased expression of GDI1 protein

NCBI chr X:152,087,611...152,094,274
Ensembl chr X:152,087,444...152,094,272

G

glutamine fructose-6-phosphate transaminase 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFPT1 mRNA

NCBI chr 4:119,496,691...119,546,472
Ensembl chr 4:119,496,714...119,546,471

G

glutamine-fructose-6-phosphate transaminase 2

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GFPT2 mRNA

NCBI chr10:34,115,005...34,161,329
Ensembl chr10:34,115,052...34,161,329

G

GDP-L-fucose synthase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFUS mRNA

NCBI chr 7:107,612,087...107,617,005
Ensembl chr 7:107,612,094...107,616,948

G

golgi-associated, olfactory signaling regulator

increases expression

Dextran Sulfate results in increased expression of GFY mRNA

NCBI chr 1:95,661,621...95,665,300
Ensembl chr 1:95,661,773...95,665,893

G

gamma-glutamyl cyclotransferase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GGCT mRNA

NCBI chr 4:84,122,921...84,129,327
Ensembl chr 4:84,123,118...84,129,277

G

gametogenetin binding protein 1

increases expression

Dextran Sulfate results in increased expression of GGNBP1 mRNA

NCBI chr20:5,109,849...5,116,185
Ensembl chr20:5,099,311...5,116,183

G

growth hormone 1

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GH mRNA

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

ghrelin and obestatin prepropeptide

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GHRL mRNA

NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621

G

galactosidase, beta 1

increases expression
multiple interactions

Dextran Sulfate results in increased expression of GLB1 protein
Erianin inhibits the reaction [Dextran Sulfate results in increased expression of GLB1 protein]

NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127

G

galactosidase, beta 1-like 2

decreases expression

Dextran Sulfate results in decreased expression of GLB1L2 mRNA

NCBI chr 8:25,115,462...25,166,843
Ensembl chr 8:25,115,462...25,166,783

G

GLI family zinc finger 1

decreases expression

Dextran Sulfate results in decreased expression of GLI1 mRNA

NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251

G

GLI family zinc finger 3

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GLI3 mRNA

NCBI chr17:49,438,567...49,709,712
Ensembl chr17:49,438,567...49,709,712

G

glucagon-like peptide 1 receptor

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GLP1R mRNA

NCBI chr20:8,972,004...9,010,241
Ensembl chr20:8,972,004...9,010,241

G

glutaminase

decreases expression
multiple interactions

Dextran Sulfate results in decreased expression of GLS protein
Erianin inhibits the reaction [Dextran Sulfate results in decreased expression of GLS protein]

NCBI chr 9:49,344,616...49,416,900
Ensembl chr 9:49,344,781...49,416,900

G

GDP-mannose 4, 6-dehydratase

multiple interactions

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GMDS mRNA

NCBI chr17:32,095,315...32,621,975
Ensembl chr17:32,095,386...32,621,961

G

G protein subunit alpha 11